
==== Front
Nanomaterials (Basel)
Nanomaterials (Basel)
nanomaterials
Nanomaterials
2079-4991
MDPI

10.3390/nano11123391
nanomaterials-11-03391
Review
Lipid-Based Nanovesicular Drug Delivery Systems
https://orcid.org/0000-0001-5510-5561
Limongi Tania *†
Susa Francesca †
Marini Monica
Allione Marco
Torre Bruno
https://orcid.org/0000-0001-6990-3126
Pisano Roberto
di Fabrizio Enzo
Felgueiras Helena P. Academic Editor
Elaissari Abdelhamid Academic Editor
Department of Applied Science and Technology, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Turin, Italy; francesca.susa@polito.it (F.S.); monica.marini@polito.it (M.M.); marco.allione@polito.it (M.A.); bruno.torre@polito.it (B.T.); roberto.pisano@polito.it (R.P.); enzo.difabrizio@polito.it (E.d.F.)
* Correspondence: tania.limongi@polito.it
† Equal contribution.

14 12 2021
12 2021
11 12 339108 11 2021
13 12 2021
© 2021 by the authors.
2021
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
In designing a new drug, considering the preferred route of administration, various requirements must be fulfilled. Active molecules pharmacokinetics should be reliable with a valuable drug profile as well as well-tolerated. Over the past 20 years, nanotechnologies have provided alternative and complementary solutions to those of an exclusively pharmaceutical chemical nature since scientists and clinicians invested in the optimization of materials and methods capable of regulating effective drug delivery at the nanometer scale. Among the many drug delivery carriers, lipid nano vesicular ones successfully support clinical candidates approaching such problems as insolubility, biodegradation, and difficulty in overcoming the skin and biological barriers such as the blood–brain one. In this review, the authors discussed the structure, the biochemical composition, and the drug delivery applications of lipid nanovesicular carriers, namely, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes, phytosomes, catanionic vesicles, and extracellular vesicles.

lipid vesicles
niosomes
proniosomes
ethosomes
transferosomes
pharmacosomes
ufasomes
phytosomes
catanionic vesicles
extracellular vesicles
==== Body
pmc1. Introduction

Despite relevant technological improvements, developing an effective and safe drug can be a complex, low success rate, time-consuming, and costly practice. As reported on the official webpage of the US Food and Drug Administration (FDA), only a small number of treatment tools (active molecules, nanoparticles, and so on) proposed as skilled medical products, after early testing, result as eligible for further study. In 2020, the FDA’s Center for Drug Evaluation and Research (CDER) authorized 53 novel therapeutics, more than double what happened from 2006–2010. More in details considering the three major therapeutic areas, the new approved drugs are 18 (34%) cancer products, 8 (15%) Neurology products, and 6 (11%) infectious diseases treatments. The average projected peak sales of a just approved drug in 2020 was about USD 700 million, and this is below a long-term average of USD 1.3 billion and a median of USD 500 million [1].

The constant development of technologies and materials resulting from the collaboration between sectors such as bioengineering, physics, chemistry, materials science, pharmacology, and not least medicine, has allowed the advancement of increasingly efficient drug delivery tools. Researchers and clinicians from all over the world daily pursue the design and implementation of increasingly personalized, safe, and cheap care solutions as new pharmacologically active molecules and nanoparticles. Recently, the application of nanoparticles (NPs) has been established to develop drug delivery efficiency. Nanomaterials generally refer to a material characterized by having at least one dimension in the nanometer scale (1–100 nm) [2], include nano-drug delivery systems that thanks to their morphological, optical, mechanical, and electrical characteristics can improve drugs’ stability and solubility by extending their blood circulation time and enhancing their delivery efficiency.

Metallic, polymeric, organic, and inorganic nano scaled materials including dendrimers, nanotubes micelles, and quantum dots (QDs) have been recently assessed as drug delivery carriers (DDC) [3,4,5].

Among the already numerous nanoscale DDCs, nanovesicles represent highly-promising effective approaches to setting up therapies against cancer, inflammation infection, and degenerative disorders.

In this review, we described the most modern lipid-based nanovesicular systems, whether they are of biological or synthetic origin, used for the most distinct biomedical and clinical applications. We left liposomes, already the subject of numerous and recent scientific publications, out of the topics covered in this review, to make room for other lipidic nanovesicles, perhaps less known, but increasingly the target of studies for drug delivery applications such as niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes, phytosomes, and catanionic vesicles. Last, but certainly not least, the type of Lipid NanoVesicles (LNV) discussed in this review are the extracellular vesicles (EVs) and their increasingly wide application as DDC of inorganic NPs, drugs, and nucleic acids. For each type of LNV category covered by the discussion, we provided an updated table listing in a very detailed way, the biochemical composition of each vesicle, its cargo, and the application for which it has been designed and studied referring to the in vitro and in vivo drug delivery applications of the last 10 years.

2. Proniosomes and Niosomes

Niosomes and proniosomes are LNV systems characterized by distinctive amphiphilic structures able to improve poorly soluble drugs bioavailability. Their uniqueness is in having a nonionic surfactant backbone while their multilamellar and unilamellar vesicles structures appear similar to that of liposomes [6] (Figure 1 and Figure 2).

It is assumed that lipophilic molecules are confined within the lipid bilayers while the hydrophilic ones are retained in the niosomes’ aqueous partitions. This efficient compartmentalization improves the stability of the enclosed drugs preventing their chemical and enzymatic degradation [7]. Proniosomes are nonionic dehydrated structured provesicles in the powdered form or in the gel states. Provesicles are water soluble dry free-flowing granular products that can be immediately rehydrated before use avoiding many issues related to aqueous vesicular dispersions. Proniosomes and niosomes can be produced by using cholesterol, non-ionic surfactants (Tween 20, 40, 80, Span 20, 40, 60, 80, 85), solvents as chloroform and methyl and ethyl alcohols and lecithin. Usually, surfactants utilized to produce niosomes and proniosomes are characterized by low aqueous solubility but Tween can be successfully used to produce micelles on hydration [8].

Niosomes are similar to liposomes, but they are cheaper, exhibit a higher stability, encapsulation efficiency, and permeability for small molecules, avoid the degradation of phospholipids by oxidation, and are easier to store and handle. Indeed, niosomes display some drawbacks, such as aggregation, fusion, and leakage of drugs, while proniosomes can overcome these issues contrasting leakage, aggregation, or hydrolysis of drugs while optimizing their storage and biodistribution, adding the possibility of sterilization, room temperature storage, and being rehydrated instantly to create niosomes [9].

Proniosomes have several pluses over niosomes, contrasting leakage, aggregation, or hydrolysis of drugs while optimizing their storage and biodistribution.

Although the first applications of non-ionic surfactant nanovesicles were cosmetic ones [10,11], in Table 1 and Table 2, we report the numerous and recent drug delivery applications for proniosomes and niosomes, respectively.

Thanks to their capability to store and deliver both hydrophilic and hydrophobic medications through topical, oral, transmucosal, pulmonary, ocular, and parenteral/intravenous administration, niosomes and proniosomes are increasingly used as vaccines and treatments for infection, inflammation, cancer, and many other acute or chronic diseases.

3. Ethosomes

Ethosomes were designed and developed in 2000 by Touitou et al. [108] as an advanced noninvasive passive lipid-based delivery system. As represented in Figure 3, these carriers are lipid bilayers composed of phospholipids, water, and high concentrations of ethanol which gives them remarkable transdermal permeability skills. Ethanol and lipid molecules act in the polar head group region increasing membrane fluidity and permeability. Ethosomes have significantly improved skin delivery, carrying the active compounds in the deeper layers of the skin in occlusive and non-occlusive conditions. In addition, they display high deformability, encapsulation efficiency, stability, biocompatibility, and a negative charge due to ethanol that leads to small vesicles size, enhancing the bioavailability of the compounds. Despite these advantages, there are some drawbacks caused by the volatile nature of ethanol, such as problems related to system instability, drug leakage, and skin irritation [109]. These vesicles are successfully used for topical administration of a considerable variety of drugs such as antifungals, antivirals, antibiotics, anti-inflammatories, and many others as detailed in Table 3.

4. Transfersomes

Many drug delivery systems have been designed over the past decades for transdermal administration, which offers many advantages over other routes thanks to its capability of escaping presystemic metabolism, tune drug release reducing variation in drug levels, enhancing pharmacological response. Compared to most other transdermal delivery methods including chemical permeation enhancers, sonophoresis, microneedles, lipid vesicles thanks to their distinctive composition can transport both hydrophilic and lipophilic drugs [140].

Among the LNV, transfersomes, first proposed in the early 1990s, are ultra-deformable elastic vesicles successfully employed as a non-occluded method able to permeate skin through the stratum corneum reaching the dermis and blood circulation [141]. As schematized in Figure 4, they are firstly characterized by an aqueous core enclosed by a lipid bilayer of amphipathic constituent as phosphatidylcholine, lecithin, or a mixture of lipids. In addition to a very low percentage of alcohol (3–10%), they are made with 10–25% of bilayer-softening complexes, surfactants, or edge activators as Tweens, Spans, sodium cholates, and deoxycholate. The appropriate phospholipids/surfactants ratio tunes transferosomes’ membrane elasticity reducing vesicles’ rupture chances through the skin [142,143]. By having edge activators in their structure, thanks to their remarkable elastic properties, transfersomes defeat many main liposomes’ weaknesses resulting in more apt to squeeze themselves through the skin barrier [144]. Despite these advantageous properties, transfersomes exhibit also some drawbacks, i.e., chemical instability due to the oxidative degradation and expensiveness in the precursors and manufacturing [143].

Thanks to their enhanced skin-penetration abilities, transfersomes are competent to set up skin drug storage area for continuous therapeutic molecules delivery releasing low, as well as high, molecular weight drugs as antioxidants, chemotherapy, anti-Inflammatory, and corticosteroids (Table 4).

5. Pharmacosomes

The name pharmacosomes refers to the amphiphilic, zwitterionic, stoichiometric complexes of polyphenolic compounds with phospholipids, as schematized in Figure 5. The success in the use of pharmacosomes is explained by the surface and bulk interactions of lipids with drugs since the latter possess an active hydrogen atom as –OH, -COOH, -NH2, which can be esterified to the lipid causing an amphiphilic compound [166,167].

The use of pharmacosomes in drug delivery has several advantages over that of other vesicles such as niosomes, transferosomes, and liposomes. More in detail, any active molecules in which a carboxyl group is present can be esterified without a spacer chain as opposed to those characterized by the presence of amino or hydroxyl groups which, in order to be esterified, require spacer groups. Pharmacosomes design is based on the phospholipids/water superficial and bulk interaction; the drug molecule and the connected lipid molecule, respectively, behave like the polar head group and the lipidic chain giving the molecule an amphipathic character. Thanks to their hydrophilic and lipophilic properties, these lipid LNV improve drugs’ dissolution in gastrointestinal fluid, increasing the bioavailability of low soluble treatments avoiding leak and rupture release [168,169]. Pharmacosomes’ in vivo pharmacokinetic performances are conditioned by vesicles’ dimension, by the drug molecule’s functional groups, by the lipids’ fatty acid chain length, and, last but not least, by the spacer groups’ availability. The high tunability of each of the components listed above makes these types of vesicles excellent candidates for the effective delivery of a wide range of active molecules including anti-cancer and anti-inflammatory remedies (Table 5) [170].

Among the few limitations relating to the use of pharmacoses, reference should be made to their susceptibility to hydrolyzation, fusion, or aggregation during storage or engineering processes [171,172].

nanomaterials-11-03391-t005_Table 5 Table 5 Pharmacosomes’ drug delivery applications.

Composition	Cargo	Application	Reference	
Doxifluridine and DOTAP	miR-122	Treatment of hepatocellular carcinoma	[173]	
Etoricoxib and phosphatidylcholine		Rheumatoid arthritis treatment	[174]	
Folic Acid-Modified 2-Deoxyglucose and amino ethanol		Targeting anti-tumor therapy	[175]	
Ibuprofen and Phosphatidylcholine from soy		Anti-inflammatory	[176]	
Levodopa, egg lecithin and chitosan		Parkison’s treatment	[177]	
Naproxen and soy lecithin		Rheumatoid arthritis treatment	[178]	
Rosuvastatin, soy lecithin and cholesterol		Hyperlipidemia treatment	[179]	

6. Ufasomes

Unsaturated fatty acid vesicles preparation, more commonly known as ufasomes, was first reported in 1973 by Gebicki and Hicks [180]. In a controlled pH range, from 7 to 9, they are a closed lipid bilayered suspension, made from unsaturated fats and their ionized species. In detail, fatty acid molecules’ hydrocarbon tails are directed toward the deeper membrane layer while the carboxyl heads are in contact with water [181], as schematized in Figure 6. Oleic and linoleic acid (cis, is-9,12-octadecadienoic acid), the major ufasomes’ constituents, confer to these nanovesicles a more versatile nature than that of the other LNV, by ranking them between different nanosystems formed from double-chain amphiphiles and from single-chain surfactants micelles. Their biochemical composition makes them easily to assemble and real biocompatible [182,183]. By enhancing ufasomes stability with the identification of the appropriate fatty acid, pH range, and lipoxygenase amount, increasingly targeted and effective drug delivery solutions are being developed (Table 6).

7. Phytosomes

Although for a long time phyto-pharmaceuticals have a prominent position in the therapeutic scene, it should be emphasized how phyto-active constituents as phenolics, flavonoid, and terpenoids demonstrate considerable in-vitro bio-action but are still characterized by low in-vivo effectiveness due to their high molecular weight, low lipid solubility, and bioavailability [188]. Phytosomes nanovesicles originating by Phyto-Phospholipid Complex (PPC), have been developed as a capable strategy to improve natural drugs delivery and bioavailability. PPCs originate by the phospholipids’ polar head and active constituents’ interactions. The two long fatty acid chains do not take part in the formation of the complex, they can interchange encapsulating the polar region of complexes originating a lipophilic side when resuspended in water (Figure 7) [189].

Phytosomes have many structural and functional aspects in common with liposomes and tranferosomes such as the capability to improve the solubility of weakly soluble polyphenolic phytochemicals. Otherwise, phytosomes and transferosomes are more stable than liposomes in 4 °C and 25 °C aqueous media up to three months since liposomes should be freeze dried to preserve their stability. Phytosomes, as well as transferosomes, exhibit superior dermal penetration properties leading noticeable accumulation in the epidermis and dermis. Since the phytosomes configuration is grounded on the H-bond interaction between the phospholipid molecules’ polar moiety and the phytoconstituents, the laded compounds permanence is higher than in other lipid nanovesicles [190]. The numerous and very recent drug delivery applications collected in Table 7 show how phytosome nanotechnology will definitely get more efficient the ways of bioactive phytochemicals therapeutic and aesthetic delivery counteracting the bottlenecks of the low absorption and poor penetration rate across biological barriers improving herbal-originated compounds pharmacodynamic and pharmacokinetic and assets [190].

8. Catanionic Vesicles

An innovative class of biocompatible and biodegradable drugs lipidic nanovehicle is represented by the catanionic vesicles for their capability to improve the stability and cellular uptake of a wide range of active molecules [215]. These hybrid nanovesicles spontaneously form when unequal amounts of cationic and anionic single-tailed surfactants are dispersed in water [216] (Figure 8).

These nanovesicles are produced by using easily accessible cheap surfactants and, in comparison with phospholipid vesicles, are thermodynamically advantaged in terms of colloidal stability. Alkyl ammonium bromide and gemini surfactants such as bis-quaternary ammonium salts have been used for catanionic vesicles production; however, since they are cytotoxic and not biodegradable, the conjugation with safer molecules is being successfully considered [217]. Their low production costs, higher stability and drug loading capability, together with the fact that they suffer less from ruptures and pressure drops make them excellent drug delivery vehicles for vaccination and anti-microbial, cancer, and inflammatory applications (Table 8). Thus, although catanionic vesicles have a huge applicability in biomedicine, they can suffer safety problems due to their eventual low bio- and emocompatibility. Numerous ongoing researches point to the optimization of their morphology, hydrophobicity, and ionic charge by carefully choosing the proper surfactant and by tuning the anionic/cationic surfactant ratio eventually adding some suited additive [218].

9. Extracellular Vesicles

The most heterogeneous and versatile class of lipid vesicles is certainly that of extracellular vesicles (EVs) (Figure 9) including apoptotic bodies, microvesicles, and exosomes. These vesicles are ubiquitarian and can be isolated from cells culture media and from all the major biological fluid as urine, plasma, saliva, amniotic and cerebrospinal fluid, semen, among others [242,243,244,245]. Both apoptotic bodies and microvesicles, with dimensions ranging between 500 nm and 2 µm and from 50 nm to 1 µm, respectively, arise from plasma cell membrane outward blebbing and fragmentation. On the other side, exosomes, deriving from the endocytic pathway, have diameters between 30 to 120 nm [246]. Many authors reported about the EVs use in drug delivery since their surface is characterized by antigens, related to the parental cells, able to direct specific homing or targeting phenomena [247]. Although the EVS, as the main physio-pathological intracellular communication mediators, are already in origin able to transport miRNA, proteins, and other biological molecules, their morpho-functional and biochemical characteristics make them excellent candidates for post isolation nanotechnological modifications. In the last twenty years, numerous studies show the great potential of these vesicles in both the diagnostic and therapeutic fields [248]. Their high biocompatibility, low immunogenicity coupled with a superior loading capability make them proper tools for post isolation drug delivery load and engineering. In addition to a whole series of chemical or biological functionalization, many studies are referring to the possibility of loading them with cellular organelles such as mitochondria, NPs, drugs, and nuclei acids [249,250,251].

Although the intrinsic complexity related to the EVs’ size and natural (batch-to-batch) heterogeneity makes their drug delivery application much more complex than that with merely synthetic production systems, many exogenous EVs’ active molecules loading methods have been successfully proposed for the clinical EVs’ translation [252] (Table 9).

Many types of cell-derived exosomes, coming from both plant and human eukaryotic cells, have recently been used to successfully encapsulate inorganic NPs. The cargo can be either loaded by treating parental cells or by post EVs isolation engineering [299]. The potential benefits of a wide range of inorganic NPs-loaded EVs have been proven in various drug delivery applications as extensively listed in Table 10.

Since EVs are remarkably involved in genetic information transfer in normal and pathological states [325,326,327], it is not difficult to see their potential as engineered nucleic acids carriers for drug the treatment of ischemic stroke, myocardial infarction [328], traumatic brain injuries [329], and liver fibrosis [330].

The intrinsic properties of EVs such as low immunogenicity and safety make them a suitable candidate for gene cancer therapy with promising advantages with respect to the conventional chemotherapeutic treatments. EVs transfer their RNA or DNA cargo to the target cells with the aim to alter the tumoral genes information and act, e.g., as tumoral suppressors. In addition, the therapeutic properties of EVs-nucleic acids loaded can be further improved by tailoring their surface [331] in order to maximize specificity and successful delivery. In Massaro et al. [332] is reported a list of the ligands used for cancer therapy. Interestingly, attempts to conjugate RNAs to molecules such as cholesterol for EVs surface functionalization were reported [333,334], with the aim to improve loading control and delivery. Therapeutics effects of Plasmid DNA, mRNA, miRNA, and shRNA delivery EV-mediated were reported in Table 11 underlining how gene therapy combined with EVs delivery is a rapidly growing field for safe and effective precision medicine treatments.

10. Conclusions

It is well known that liposomes, assumed to be the oldest category of lipidic nanovesicles, have been broadly considered as the major candidates for biomedical and drug delivery applications. Despite their high biocompatibility and the ability to effectively carry both hydrophilic and/or hydrophobic active molecules to the target site, they still suffer some unresolved weaknesses such as brief shelf-life, low colloidal stability, and limited and expensive preparation methods [389]. The development of new drug delivery approaches has significantly boosted the design and the production of the just reviewed non-liposomal lipid nanovesicles. This new cohort of lipid vesicles can complement liposomes as alternative nanovesicular drug delivery systems and although recently implemented, they have all the chances to overspread as successful engineered nanomaterials.

Considering the existent non-liposomal LNV, those collected in this review, given their countless listed applications, have undoubtedly proved to be the most successful ones by reaching clinical use. Surely among the different types of LNV described in this review, those of cellular origin, the extracellular vesicles, are those that could also give future results closer to the needs of personalized medicine therapeutic plans. The possibility of isolating them from the same patient who is going to be treated reduces the likelihood of rejection phenomena both by increasing the compliance of the therapy and by reducing any adverse effects. Therefore, it would be foreseen that very soon, the LNV carrier’s production will scale-up from the lab scale to the industrial one issuing high-quality competitive outcomes.

In this regard, we would like to conclude with an update on the recent and promising use of lipid nanovesicles for the nucleic acids based-vaccine development. This application has been mainly oriented to the oncologic field, but recently, under the pressure of the latest terrible health emergency that has afflicted the entire globe, anti-viral applications have been reported. EV-based vaccines to deliver mRNA coding for specific molecules such as proteins or by the exposure of specific features on EVs surface have been designed. Since 2020, the SARS-CoV-2 pandemic has boosted additional efforts for the successful design of forceful vaccines [332,390]. Leading approved vaccines provide immunization by the viral Spike (S) protein, injected as purified proteins or codified by the administered mRNAs sequences and showing that “mRNA-based vaccines can fill the gap between emerging pandemic infectious disease and a bountiful supply of effective vaccines” [391]. The mRNA-based vaccine BNT162b2 was developed by Pfizer/BioNTech while the mRNA-1273 SARS-CoV-2 vaccine was developed by Moderna [392]. In Tsai et al. [364] was reported another approach for SARS-CoV-2 vaccines: exosomes are used to deliver mRNAs sequences with the aim to express not only the spike protein but also another artificial protein named “LSNME” and containing the viral spike, nucleocapsid, membrane, and envelope proteins. This approach has been tested on mice with promising results and, along with the many other applications reported in this review, confirmed the growing potential of lipid nanovesicles-mediated delivery as an effective tool for the translation of nanotechnology, bioengineering, and nanomaterials studies from research to clinic.

Author Contributions

Conceptualization, T.L. and F.S.; resources, T.L., F.S.; writing—original draft preparation, T.L. and F.S; writing—review and editing, M.M., B.T., M.A., R.P. and E.d.F. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Data presented in this manuscript is available from corresponding author upon reseanable requests.

Conflicts of Interest

The authors declare no conflict of interest.

Figure 1 Structure of proniosomes lipid vesicular systems.

Figure 2 Structure of niosomes lipid vesicular systems.

Figure 3 Schematic structure of ethosome lipid vesicular system.

Figure 4 Schematic structure of transfersomes lipid vesicular system.

Figure 5 Schematic structure of pharmacosomes lipid vesicular system.

Figure 6 Schematic structure of ufasomes lipid vesicular system.

Figure 7 Schematic structure of phytosomes lipid vesicular system.

Figure 8 Schematic structure of catanionic vesicles.

Figure 9 Schematic structure of extracellular vesicles.

nanomaterials-11-03391-t001_Table 1 Table 1 Proniosomes’ drug delivery applications.

Composition	Cargo	Application	Reference	
Cholesterol, Span 60 and maltodextrin	Aceclofenac	Anti-inflammatory in osteoarthritis	[12]	
Cholesterol, Span 60, maltodextrin and stearylamine	Acemetacin	Anti-inflammatory	[13]	
Cholesterol, lecithin, Span 60 and Span 40	Atenolol	Hypertension treatment	[14]	
Cholesterol, lecithin and Tween 80	Atorvastatin calcium	Anti- hyperlipidemic	[15]	
Cholesterol, lecithin and Span 40	Boswellic acid	Anti-inflammatory	[16]	
Cholesterol, lecithin and Span 60	Caffeine	Migraine treatment	[17]	
Cholesterol and Span 60	Cilostazole	Anti-platelet	[18]	
Cholesterol, lecithin and Span 60	Clozapine	Treatment of psychiatric disorders	[19]	
Cholesterol, lecithin and cremophor RH	Curcumin	Against ocular inflammation	[20]	
Cholesterol, Span 60 and Tween 80	Ciprofloxacin	Anti-inflammatory	[6]	
Cholesterol, Span 40 TPGS	Docetaxel	Anticancer treatment	[21]	
Cholesterol and Span 60	Famotidine	H2 receptor antagonist	[22]	
Cholesterol, Sorbitol and Span 80	Flurbiprofen	Anti-inflammatory	[23]	
Cholesterol and Brij35	D-limonene	Cancer therapy	[24]	
Cholesterol, Span 60	Itroconazole	Antimicotic against candida albicans	[25]	
Cholesterol, lecithin and cremophor RH 40	Lacidipine	Treatment of hypertension and atherosclerosis	[26]	
Cholesterol, Tween 80, sorbitol and sucrose	Letrozole	Breast cancer	[27]	
Cholesterol, Span 80 and lecithin	Lignocaine Hydrochloride	Dental anesthesia	[28]	
Cholesterol, Span 60 and Tween 60	Lomefloxacin HCl	Treatment of bacterial conjunctivitis	[29]	
Cholesterol, lecithin and Lutrol F68	Lornoxicam	Anti-inflammatory for rheumatoid arthritis, osteoarthritis and surgeries	[30]	
Cholesterol, lecithin and Span 60	Embelin	Analgesic and anti-inflammatory	[31,32]	
Span 40, Span 60, and Brij series 72	Fluconazole	Management of dental pain	[33]	
Cholesterol, lecithin and Span 60	Naproxen	Anti-inflammatory	[32]	
Cholesterol, Span 60 and maltodextrin	Pentazocine	Management of cancer pain	[34]	
Cholesterol, Span 60, maltodextrin, pullulan and DPPH	Resveratrol	Controlling free radicals causing oxidative stress-induced cardiovascular diseases, atherosclerosis, cancer	[35]	
Cholesterol, Span 60, lecithin and stearylamine	Risperidone	Treatment of schizophrenia and other psychiatric disorders	[36]	
Cholesterol, lecithin and Span 80	Tramadol	Anti-inflammatory and antinociceptive	[37]	
Cholesterol, Span 60, lactose and mannitol	Vismodegib	Carrier for the pulmonary route	[38]	

nanomaterials-11-03391-t002_Table 2 Table 2 Niosomes’ drug delivery applications.

Composition	Cargo	Application	Reference	
Span 60, cholesterol and bile salt	Acetazolamide	Decrease ocular pressure in glaucoma patients	[39]	
Span 60, cholesterol, HMPC and carbopol	Acetazolamide and carvedilol	Decrease ocular pression in glaucoma patients	[40]	
Cholesterol, lecithin, Span 60 and Tween 60	Acyclovir	Antiviral	[41]	
Span60, Cholesterol and DCP or Span60, Cholesterol and TPGS	[42]	
Cholesterol and Span 40	Betaxolol	Glaucoma treatment	[43]	
Ergosterol, Span 60 and Tween 60	Carum	Anticancer	[44]	
Cholesterol and Span/Tween 60	Carvedilol	Congestive heart failure, coronary artery disease, postmyocardial settings	[45]	
Bile salt-enriched vesicles, with 20% sodium cholate and 30% sodium taurocholate	Beta receptor blocking activity to preclude angina and cardiac arrhythmias	[46]	
Cholesterol, Span 60 and Tween 60	Cephalexin	Antibacterial	[47]	
Cholesterol, Span 40 and Tween 40	Ciprofloxacin	Antibacterial	[48]	
Cholesterol, Span 60 and Tween 60	[49]	
Cholesterol, span and tween 20	Curcumin	Antinociceptive and anti-inflammatory	[50]	
Cholesterol, Span 80, PEG	Daunorubicin and anti-CD123	Treatment of acute myeloid leukemia	[51]	
Cholesterol, Span 40 and tween 40	D-limonene	Cancer therapy	[52]	
Pluronic L64, Tween 60, EMG 707 Ferrofluid	Doxorubicin	Therapy against chronic myelogenous leukemia	[53]	
Pluronic L64, Cholesterol and transferrin	Cancer therapy	[54]	
Cholesterol, Span 40 and tween 40	Doxorubicin and Hydrophobin-1	Cancer therapy	[55]	
Cholesterol and Span 60	Doxorubicin and N-lauryl glucosamine	Targeted cancer therapy	[56]	
Cholesterol, Span 60 and Tween 60	Doxycyclin	Treatment of infection-associated prostate cancer	[57]	
Cholesterol and Span 60	Doxycyclin hyclate	Management of ocular diseases	[58]	
Cholesterol, Span 60 and phospholipid 90G	Embelin	Diabetes treatment	[59]	
Span 40, Span 60, and Brij series 72	Fluconazole	Antifungal treatments	[60]	
Cholesterol and Span 60	Flurbiprofen	Anti-inflammatory	[61]	
Cholesterol, Span 60 and Tween 65	Gemcitabine and cisplatin	Lung cancer treatment	[62]	
Cholesterol, Span 40 and Tween 80	Levofloxacin	Antibacterial	[63]	
Cholesterol and Span 60	Linezolid	Antibacterial	[64]	
Cholesterol, Span 80 and Tween 80	Methotrexate	Solid tumor treatment	[65]	
Span 60, PVA and cremophor RH40	[66]	
Cholesterol and glucopyranoside	[67]	
Cholesterol and Span 40	Metformin hydrochloride	Avoid Metformin-associated lactic acidosis in the treatment of diabetes mellitus	[68]	
Cholesterol and Span 60	Minocyclin	Antibacterial coating of dental implants	[69]	
Cholesterol and Tween 60	Moxifloxacin	Antimicrobial	[70]	
Cholesterol and tyloxapol	Nevirapine	HIV treatment	[71]	
Cholesterol, Span 60 and SolulanC24	N-palmitoylglucosamine	Brain targeting of dynorphin-B	[72]	
Cholesterol, Span 60 and PEG	Simvastatin	Against myocardial ischemia/reperfusion injury	[73]	
Cholesterol, Span 20 and Span 60	Pediatric transdermal dyslipidemia treatment	[74]	
Cholesterol and sorbitan monostearate	Tamoxifen citrate	Incorporated in hydrogel as a pH-responsive drug delivery for breast cancer treatment	[75]	
Cholesterol and Span 20	Tamoxifen citrate and doxorubicin	Breast cancer treatment	[76]	
Cholesterol, Span60, PEG and TAT peptide	Tenofovir	HIV treatment	[77]	
Cholesterol, Span 60 and Tween 40	Timolol maleate	Glaucoma treatment	[78]	
Cholesterol and Span 60	[79]	
Cholesterol and Span 40		
Cholesterol and Span 60	Timolol maleate and Brimonidine tartrate	Glaucoma treatment	[80]	
Cholesterol, Span 60 and Tween 60	Tobramycin	Antibacterial	[81]	
Cholesterol, Span 60 and Tween 40	Vancomycin	Antibacterial	[82]	
Cholesterol and Span 60	Antibacterial coating for bone plates	[83]	
Cholesterol and Tween 40	Zolmitriptan	Migraine treatment	[84]	
Cholesterol and Span 60	Chlorotoxin and temozolomide	Targeting and treatment of glyomas	[85]	
Cholesterol, Span 60 and PEG	Doxorubicin, curcumin and tLyp-1 peptide	Glioblastoma treatment	[86]	
PEG, Tween 80, Octadecylamine	Akt 1 siRNA, Au NPs and Thymoquinone	Treatment of resistance in breast cancer	[87]	
Span 80 and PEG	BBIQ [Toll-like receptor (TLR) 7 agonist] and D-1MT [Indoleamine2, 3-dioxygenase (IDO) inhibitor]	Cancer vaccine	[88]	
Tween 80 and DTPA-Cl	BMP-7 plasmid	Bone regeneration	[89,90]	
Cholesterol and Span 60	CD9 and CD63 tetraspanins	Exosomes immunoassays	[90]	
Cholesterol, monopalmitin and Dicetyl phosphate	Influenza antigen	Vaccine and immune response	[91]	
Cholesterol, Span 80 and Tween 80	NLS-Mu-Mu fusion protein	Gene delivery	[92]	
Tween 60, DOTMA and lycopene	pCMS-EGFP plasmid	Gene delivery to the brain	[93]	
Cholesterol, Span 20 and plier-like cationic lipid A (PCL-A)	pDNA or siRNA	Nucleic acid delivery	[94]	
DOTMA, Tween 20 and Squalene	pEGFP, pGFP, MC-GFP	Treatment of inherited retinal diseases	[95]	
Cholesterol and Span 20	pH (Low) insertion peptide (pHLIP)	Tumor targeting	[96]	
Cholesterol, Tween 20 and cationic lipid (N1,N1-dimyristeroyloxyethyl-spermine)	plasmid DNA-encoding ovalbumin (pOVA)	Skin vaccination	[97]	
2,3-di(tetradecyloxy)propan-1-amine cationic lipid, squalene and Tween 80	Plasmid pCMS-EGFP	Delivery of genetic materials to the retina	[98]	
Cholesterol and Span 60	Protective antigen (PA) and PA domain 4 (D4) of Bacillus anthracis	prophylaxis against anthrax	[99]	
Span 80, DOTAP, TPGS and indocyanine green	siGFP, anti-miR-138	Promote osteogenesis in hMSCs, theranostic applications	[100]	
Cholesterol, Tween 85 and DDAB	siRNA	Melanoma treatment	[101]	
Cholesterol, Span 20 and plier-like cationic lipid B (PCL-B)	siRNA against anti-apoptotic genes (Mcl-1, Bcl-2 and survivin) and doxorubicin	Breast cancer therapy	[102]	
Cholesterol, Span 60 and PEG	siRNA/proteamine and iron superparamagnetic NPs	Breast cancer therapy	[103]	
Cholesterol, DOTAP, PEG and Tween 60	siRNA targeted the CDC20 mRNA, doxorubicin and quercetin	Cancer treatment	[104]	
Cholesterol and Tween 80	Ciprofloxacin, rifabutin and lignin Ag NPs	Antibacterial	[105]	
Cholesterol and Span 80	Curcumin and Ag/Cu NPs	Antibacterial	[106]	
Ergosterol, Span 60 and Tween 60	Protamine-condensed DNA and Fe3O4 NPs	Magnetic properties and cargo-targeted delivery	[107]	

nanomaterials-11-03391-t003_Table 3 Table 3 Ethosomes’ drug delivery applications.

Composition	Cargo	Application	Reference	
Soy lecithin	5-Aminolevulinic acid	Treatment of hypertrophic scars	[110]	
Soy phosphatidylcholine	5-fluorouracil	Treatment of skin cancers	[111,112]	
Soy lecithin and cholesterol	Apixaban	Anticoagulant	[113]	
Soy phosphatidylcholine	Azelaic acid	Treatment of acne	[114]	
Soy phosphatidylcholine and cholesterol	Boswellic acid	Anti-inflammatory	[115]	
Phosphatidylcholine	Caffeic acid	Antioxidant	[116]	
Soy lecithin	Curcumin and glycyrrhetinic acid	Psoriasis treatment	[117]	
DSPE-PEG2000, hydrogenated soy phospholipids and cholesterol	Curcumin, hyaluronic acid and CD44	Psoriasis treatment	[118]	
Soy phosphatidylcholine, polyethylenimine and sodium cholate	Doxorubicin and curcumin	Melanoma treatment	[119]	
Lecithin and Tween 80	Fenretinide	Chemopreventive for breast cancer	[120]	
Soy phosphatidylcholine, cremophor-A25 and chitosan	Ferrous chlorophyllin	Photodynamic therapy for the treatment of squamous cell carcinoma	[121]	
Phospholipid 90G	Fisetin	Skin cancers treatment	[122]	
Soy phosphatidylcholine	Flurbiprofen	Anti-inflammatory	[123]	
Soy phosphatidylcholine	Griseofulvin	Antifungal treatment	[124]	
Cholesterol and lecithin	Hyaluronic acid	Transdermal delivery of drugs	[125]	
Soy phosphatidylcholine, cholesterol	HRP IgG	Transdermal delivery of vaccines	[126]	
Soy phosphatidylcholine, cholesterol and deoxycholic acid	Indomethacin	Treatment of pain and inflammation in rheumatoid arthritis	[127]	
Soy lecithin and cholesterol	Luteolin	Anti-tumor activity in hepatocellular carcinoma	[128]	
Soy lecithin	Methotrexate	Treatment of psoriasis	[129]	
Soy phosphatidylcholine	Methoxsalen	Treatment of vitiligo	[130]	
Soy phosphatidylcholine, cholesterol and mannitol	Paenolol	Anti-inflammatory, antidiabetic and pain-relieving	[131]	
Soy phosphatidylcholine	Paeoniflorin	Arthritis therapy	[132]	
Soy phosphatidylcholine and cholesterol	Phenylethyl resorcinol	Skin Lightening Applications	[133]	
Soy phosphatidylcholine, stearylamine and propylene glycol	Resveratrol	Antioxidant	[134]	
Phosphatidylcholine	Retinyl palmitate	Acne treatment	[135]	
Soy phosphatidylcholine	Sulforaphane	Treatment of skin cancers	[136]	
Soy phosphatidylcholine	Terbinafine hydrochloride	Antifungal treatment	[137]	
Phospholipid 90G	Thymoquinone	Treatment of acne	[138]	
Soy phosphatidylcholine and cholesterol	Thymosin β-4	Wound repair	[139]	

nanomaterials-11-03391-t004_Table 4 Table 4 Transfersomes’ drug delivery applications.

Composition	Cargo	Application	Reference	
Soy lecithin and Span 80	Aceclofenac	Anti-inflammatory in osteoarthritis	[145]	
Soy phosphatidylcholine and Tween 80	Baicalin	Treatment of skin wounds	[146]	
Soy phosphatidylcholine and Tween 80	Carvedilol	Prevent skin carcinogenesis	[147]	
Phospholipon® 90G and sodium cholate	Cilnidipine	Treatment of hypertension	[148]	
Soy phosphatidylcholine	Deferoxamine	Treatment of pressure ulcers	[149]	
DPPC, cholesterol, TPGS and folate	Docetaxel	Treatment of glioblastoma multiforme	[150]	
Soy phosphatidylcholine and sodium cholate	Epigallocatechin-3-gallate and hyaluronic acid	Anti-aging and antioxidant	[151]	
Soy phosphatidylcholine and Tween 80	Eprosartan mesylate	Treatment of hypertension	[152]	
Soy phosphatidylcholine and Span 80	Genistein (GEN-TF2)	Therapeutic or preventive strategy against neurodegenerative diseases	[153]	
Soy lecithin and Sodium Lauryl Sulphate	Ivabradine HCl	Treatment of stable angina pectoris	[154]	
Soy lecithin and Tween 80	Mangiferin	Treatment of skin wounds	[155]	
Phospholipon (PL) 90H and Span 60	Natamycin	Antifungal	[156]	
Phospholipon 90 G® and sodium cholate	Pentoxifylline	Treatment of intermittent claudication and chronic occlusive arterial diseases	[157]	
Lecithin and Tween 20/80	Resveratrol	Antioxidant	[158]	
Soy phosphatidylcholine, Tween 80 and ceramide III	Retinyl palmitate	Antioxidant	[159]	
Soy phosphatidylcholine and emu oil	Tamoxifen	Transdermal therapy for breast cancer	[160]	
Soy lecithin and Tween 80	Taxifolin	Antioxidant	[161]	
Soy phosphatidylcholine and Tween 80	Tocopherol	Antioxidant	[162]	
Soya lecithin and Tween 80	Zolmitriptan	Migraine treatment	[163]	
Soy lecithin and sodium deoxycholate	Human growth hormone	Transdermal hormone delivery	[164]	
Egg phosphatidylcholine, stearylamine and Tween 20	PnPP-19 peptide	Treatment of erectile dysfunction	[165]	

nanomaterials-11-03391-t006_Table 6 Table 6 Ufasomes’ drug delivery applications.

Composition	Cargo	Application	Reference	
Cholesterol and oleic acid	Cinnarizine	Antihistaminic activity	[184]	
Phosphatidylcholine from soy
and oleic acid	Minoxidil	Hypertension treatment	[185]	
Phosphatidylcholine from soy
oleic and linoleic acid	Oleuropein	Antioxidant activity	[183]	
Oleic acid and tea tree oil	Oxiconazole	Candida albicans treatment	[186]	
Glyceryl oleate	Terbinafine hydrochloride	Candida albicans treatment	[187]	

nanomaterials-11-03391-t007_Table 7 Table 7 Phytosomes’ drug delivery applications.

Composition	Cargo	Application	Reference	
Phosphatidylcholine	Abutilon indicum and Piper longum	Hepatoprotective effect	[191]	
Phosphatidylcholine	Annona muricata L. aqueous extract	Treatment of major depressive disorders	[192]	
Milk phospholipids	Ascorbic acid and α-tocopherol	Antioxidative	[193]	
Phosphatidylcholine	Berberine	Diabetes treatment	[194]	
Phosphatidylcholine	Chicoric acid and chlorogenic acid from the Echinacea plant	Antioxidant activity	[195]	
Egg phospholipid	Chrysin	Diabetes treatment	[196,197]	
Lecithin	Diosgenin	Lung cancer treatment	[198]	
Phosphatidylcholine	Diosmin	Vascular protection activity	[199]	
Phosphatidylcholine and piperine	Domperidone	Anti-emetic effect	[200]	
Lecithin	Ethanolic extract of leaves of Bombax ceiba	Hepatoprotective effect	[201]	
Lipoid® S45	Flavonoids from Citrullus colocynthis, mormodica balsamina l. and mormodica dioica roxb.	Diabetes treatment	[202]	
Lipoid® S100 and Phosal® 75 SA	Genistein	Hepatocellular carcinoma treatment	[203]	
Soy Hydrogenated Phosphatidylcholine	Icariin	Treatment of ovarian cancer	[204]	
Phosphatidylcholine	Momordica charantia extract	Hypoglycemic effect	[205]	
DPPH and phosphatidylcholine	Persimmon extract	Antioxidative	[206]	
Phosphatidylcholine	Propolis	Antioxidant activity	[207]	
DPPC	Rutin	Antioxidant for the prevention of liver inflammation	[208]	
Lecithin	Silymarin	Antioxidant, hepatoprotective and anticancer activity	[209]	
Lecithin	Taxifolin rich fraction of Cedrus deodara bark extract	Breast cancer treatment	[210]	
Soy Hydrogenated Phosphatidylcholine	Thymoquinone	Lung cancer treatment	[211]	
Phosphatidylcholine	Tripterine	Cancer treatment	[212]	
Lipoid S100	Tripterine and selenium	Arthritis treatment	[213]	
Phosphatidylcholine	Umbelliferone	Photo-protective and antioxidant activity	[214]	

nanomaterials-11-03391-t008_Table 8 Table 8 Catanionic vesicles’ drug delivery applications. In the composition column, C is the cationic and A the anionic compound.

Composition	Cargo	Application	Reference	
C: ester functionalized morpholinium and imidazolium-based surface active ionic liquids
A: sodium butyrate	Curcumin	Antimicrobial activity	[219]	
C: CTAB
A: SDS	Lung cancer treatment	[220]	
C: CTAB
A: SDS	Diclofenac sodium	Anti-inflammatory	[221]	
Serine-based surfactants
C: 16Ser
A: 8-8Ser	Doxorubicin	Cancer treatment	[222]	
C: 4-cholesterocarbonyl-4′-(N,N,N-triethylamine butyloxyl bromide) azobenzene
A: SDS	Antioxidant activity	[223]	
C: CTAT
A: sodium dodecylbenzenesulfonate	Francisella tularensis lisate	Tularemia vaccine	[224]	
C: benzyldimethylhexadecyl
ammonium chloride
A: sodium 1,4-bis (2-ethylhexyl) sulfosuccinate	Insulin	Diabetes treatment	[225]	
C: Azobenzene-based surfactant
A: sodium dodecylbenzenesulfonate	Paclitaxel and Bcl-2 siRNA	Breast cancer treatment	[226]	
C: hexadecyltrimethyl ammonium copper trichloride
A: SDS	Toluidine blue and Rose Bengal	Antimicrobial Photodynamic Therapy against Escherichia coli	[227,228]	
C: CTAC
A: SDS	Trans-resveratrol	Antioxidant and radical scavenging activity	[229]	
C: arginine-based surfactants
A: sodium laurate, sodium myristate and 8-SH		Antimicrobial and antibiofilm activity	[218]	
C: cetalkonium chloride
A: diclofenac sodium, flurbiprofen sodium or naproxen sodium		Anti-inflammatory drug release from contact lenses	[230]	
C: chlorambucil prodrug
A: sodium bis (2-ethylhexyl) sulfosuccinate		Cancer treatment	[231]	
C: Cytarabine hydrochloride
A: Sericin protein surfactant		Cancer treatment	[232]	
C: CTAT
A: sodium dodecylbenzenesulfonate		Extraction of cell surface components of Neisseria gonorrhoeae into the leaflet of the vesicles to create artificial pathogens for vaccines	[233]	
C: doxorubicin
A: gemini surfactant		Cancer treatment	[234]	
C: DTAB
A: dioctyl sulfosuccinate sodium salt		Drug delivery for cystic fibrosis	[235]	
C: hexamethylene-1,6-bis (dodecyldimethylammonium) dibromide
A: diclofenac sodium		Antimicrobial activity	[236]	
C: methylimidazolium- or pyridinium-based surface active ionic liquids
A: sodium N-lauroyl sarcosinate		Antimicrobial activity	[237]	
C: methylimidazolium- or pyridinium-based surface active ionic liquids
A: sodium bis(2-ethyl-1-hexyl) sulfosuccinate		Antimicrobial activity	[238]	
C: NαNω-Bis(Nαcaproylarginine) α,ω-propyldiamide
A: Lichenysin		Antimicrobial and antifungal activity	[239]	
C: N(π), N(τ)-bis(methyl)-L-Histidine tetradecyl amide
A: lysine-based surfactant Nα-lauroyl-Nεacetyl lysine or sodium myristate		Antimicrobial activity	[240]	
C: N-dodecylamino-1-deoxylactitol
A: ketoprofen		Anti-inflammatory activity	[241]	

nanomaterials-11-03391-t009_Table 9 Table 9 Extracellular vesicles’ drug delivery applications.

Parental cell	Cargo	Application	Reference	
EVs from HEK293T cells	Angiotensin converting enzyme II (ACE2)	Protect from SARS-CoV-2 infection by competitively bound to virus against host cells	[253]	
Milk-derived exosomes	Anthocyanidins	Anti-proliferative and anti-inflammatory in lung cancer	[254]	
Exosomes from breast and colorectal cancer cells	Aspirin	Cancer therapy	[255]	
Exosomes from MIN-6 cells	BAY55-9837	Increase insulin production for type 2 diabetes mellitus	[256]	
Exosomes from macrophages	Berberine	Spinal cord injury treatment	[257]	
EVs from human umbilical cord mesenchymal stem cells	Cannabidiol	Increase the therapeutic efficacy of doxorubicin in triple negative breast cancer	[258]	
Exosomes from umbilical cord-derived macrophages	Cisplatin	Ovarian cancer cells treatment	[259]	
EVs from macrophages	Curcumin	Neuroprotection and ischemia-reperfusion injury treatment	[260]	
Inhibit the phosphorylation of Tau protein	[261]	
Exosomes from mesenchymal stem cells	Attenuate the progression of osteoarthritis	[262]	
EVs from HEK293 cells	Myocardial infarction treatment	[263]	
Exosomes from bone marrow-derived mesenchymal stem cells	Cerebral ischemia treatment	[264]	
Exosomes from HEK293 cells	Curcumin and RAGE-binding peptide	Acute lung injury treatment	[265]	
EVs from smooth muscle cells	Cystatin C	Protection and healing of the nervous system in different neurotoxic conditions	[266]	
Exosomes from lung cancer	Docetaxel	Non-small cell lung cancer treatment	[267]	
Exosomes from cervical cancer	Cervical cancer treatment	[268]	
Exosomes from blood samples	Dopamine	Parkinson’s disease treatment	[269]	
EVs from macrophages	Doxorubicin	Metastatic ovarian cancer treatment	[270]	
Exosomes from mesenchymal stem cells	Colorectal cancer treatment	[271]	
Exosomes from human glioma	Glioma treatment	[272]	
Milk-derived exosomes	Cancer treatment	[273]	
Exosomes from HEK293 cells	Cancer treatment	[274]	
Exosomes from bone marrow-derived mesenchymal stem cells	Osteosarcoma treatment	[275]	
Exosomes from colon cancer	Colorectal cancer treatment	[276]	
Exosomes from human breast and ovarian cancer	Breast and ovarian cancer treatment	[277]	
Exosomes from macrophages	Edaravone	Permanent middle cerebral artery occlusion treatment	[278]	
Exosomes from human fetal lung fibroblasts	Erastin	Triple-negative breast cancer therapy	[279]	
Exosomes from pancreatic cells	Gemcitabine	Pancreatic cancer treatment	[280]	
EVs from human plasma	Imperialine	Non-small cell lung cancer treatment	[281]	
EVs from human umbilical vascular endothelial cells	Meta-tetra(hydroxyphenyl) chlorine	Cancer photodynamic therapy	[282,283]	
EVs from fibroblast cells	Methotrexate	Glioblastoma treatment	[284]	
Exosomes from embryonic stem cells	Paclitaxel	Glioblastoma treatment	[285]	
Exosomes from mesenchymal stem cells	Carcinoma treatment	[286]	
EVs from gingival mesenchymal stromal cells	Cancer treatment	[287,288]	
Exosomes from macrophages	Pulmonary metastases treatment	[289]	
Milk-derived exosomes	Lung cancer treatment	[290]	
EVs from bone marrow mesenchymal stromal cells	Malignant pleural mesothelioma treatment	[291]	
Exosomes from macrophages	Multiple drug-resistant cancer treatment	[292]	
EVs from lung cancer cells	Paclitaxel and oncolytic virus	Primary and metastatic cancer treatment	[293]	
EVs from neutrophil-like cells	Piceatannol	Alleviated acute lung inflammation/injury and sepsis induced by lipopolysaccharide	[294]	
Exosomes from plasma	Quercetin	Relieve symptoms of Alzheimer’s disease by inhibiting phosphorylation of Tau and reducing the formation of insoluble neurofibrillary tangles	[295]	
Exosomes from human ovarian cancer	Triptolide	Ovarian cancer treatment	[296]	
Mannosylated exosomes from macrophages	Vancomycin and lysostaphin	Eradication of intracellular quiescent MRSA	[297]	
Exosomes from fibroblasts	WNT3A	Repair of osteochondral defects	[298]	

nanomaterials-11-03391-t010_Table 10 Table 10 Extracellular vesicles’ inorganic NPs delivery applications.

Parental Cell	Cargo	Application	Reference	
Exosomes from human hepatocarcinoma	Doxorubicin-loaded biomimetic porous silicon NPs	Cytotoxicity against bulk cancer cells and cancer stem cells	[300]	
Grapefruit EVs	Doxorubicin-loaded heparin-based NPs	Glioma treatment	[301]	
Exosomes from melanoma cells	Gold NPs	Cancer treatment	[302]	
Exosomes from HEK293T cells	Blood-brain barrier penetration and brain disorders future treatments	[303]	
Exosomes from bone marrow mesenchymal stromal cells	Neuroimaging for various brain disorders	[304]	
Exosomes from mesenchymal stem cells	[305]	
Exosomes from breast cancer cells	Gold iron oxide hybrid NPs	MRI contrast agent and photodynamic therapy	[306]	
Exosomes from mesenchymal stem cells	Iron oxide NPs	Myocardial infarction treatment	[307]	
Wound repair	[308]	
Increase activation and migration ability of macrophage	[309]	
Tumor cell ablation via magnetically induced hyperthermia	[310]	
EVs from human umbilical vascular endothelial cells	Photodynamic and hyperthermia therapy of prostate cancer	[311]	
Exosomes from macrophages	Laurate-functionalized Pt(IV) prodrug, human serum albumin, and lecithin NPs	Breast cancer and metastatic breast cancer lung nodules treatment	[312]	
Exosomes from lung adenocarcinoma cells	Metal-organic framework	Detection of the ATP level in living cancer cells, providing an efficient tool for the cell metabolism study	[313]	
Exosomes from triple negative breast cancer cells	Delivery of anticancer compounds	[314]	
Exosomes from HeLa cells	[315]	
Exosomes from lung cancer or glioma	Palladium nanosheet	Deliver catalytic cargo directly to cancer cells	[316]	
Exosomes from triple negative breast cancer cells	PLGA NPs	Cancer therapy	[317]	
Exosomes from lung carcinoma cells		[318]	
EVs from Staphylococcus aureus	Intracellular delivery of antibiotics for intracellular pathogen-associated complications treatment	[319]	
Exosomes from breast cancer	Quantum dots of vanadium carbide	Cancer photothermal therapy	[320]	
Exosomes from hepatocellular carcinoma	Silver and iron NCs	Cancer bioimaging	[321]	
Exosomes from macrophages	SPIONs and curcumin	Synergistic antitumor therapy in gliomas	[322]	
Exosomes from plasma	Superparamagnetic magnetite colloidal nanocrystal clusters	Cancer treatment	[323]	
EVs from KB cells	Zinc oxide NCs	Cancer treatment	[324]	

nanomaterials-11-03391-t011_Table 11 Table 11 Extracellular vesicles’ nucleic acids delivery applications.

Parental Cell	Cargo	Application	Reference	
Microvesicles from breast cancer cells	Minicircle DNA encoding a thymidine kinase /nitroreductase fusion protein	Breast cancer therapy	[335]	
EVs from mice melanoma cells	Plasmid DNA coding for ESAT-6	Promote antitumor activity of dendritic cells	[336]	
EVs from human brain endothelial cells and macrophages	Plasmid DNA encoding for brain-derived neurotrophic factor	Protection of the brain endothelium increasing endothelial ATP levels	[337]	
EVs from macrophage cells	Tripeptidyl peptidase-1-encoding plasmid DNA	Lysosomal storage disorder, Neuronal Ceroid Lipofuscinoses 2 (CLN2) or Batten disease treatment	[338]	
EVs from red blood cells	Anti-miR-125b ASOs and Cas9 mRNA	Cancer treatment	[339]	
Exosomes from mouse neuronal cells	miR-21-5p	Suppression of autophagy after a traumatic brain injury	[340]	
EVs from frozen human plasma	miR-31 and miR-451a	Promoted apoptosis of hepatocellular carcinoma	[341]	
Exosomes from human bone marrow mesenchymal stem cells	miR-101-3p	Oral cancer treatment	[342]	
Exosomes from bone marrow mesenchymal stem cells	miR-124	Promote neurogenesis after ischemia	[343]	
EVs from human adipose tissue-derived mesenchymal stromal/ medicinal signaling cells	miR-125b	Inhibits hepatocellular carcinoma proliferation	[344]	
Exosomes from normal intestinal epithelial FHC cells	miR-128-3p	Increase chemosensitivity of oxaliplatin-resistant colorectal cancer	[345]	
Exosomes from HKT293T cells	Curcumin, saponin, MiR-143	Engineered exosomes for anti-HIV agents delivery to solid tissues	[346]	
Exosomes from human umbilical cord mesenchymal stem cells	miR-145-5p	Inhibit adenocarcinoma progression	[347]	
EVs from bone-marrow mesenchymal stem cells	miR-146a	Ulcerative colitis treatment	[348]	
EVs from human mesenchymal stromal cells	miR-146a-5p	Prevent group 2 innate lymphoid cells -dominant allergic airway inflammation	[349]	
Exosomes from human umbilical cord mesenchymal stem cells	miR-148b-3p	Suppress breast cancer progression	[350]	
Exosomes from mesenchymal stem cells	miR-199a	Inhibit the growth of glioma by down-regulating AGAP2	[351]	
Exosomes from endothelial progenitor cells	miR-210	Protect endothelial cells against hypoxia/ reoxygenation injury improving mitochondrial function	[352]	
EVs from mesenchymal stem cells	miR-210
	Promote angiogenesis in myocardial infarction	[353]	
EVs from bone mesenchymal stem cells	miR-216a-5p	Promote the proliferation of chondrocytes in osteoarthritis	[354]	
EVs from human umbilical cord mesenchymal stem cells	miR-302a	Therapy of endometrial cancer	[355]	
EVs from mesenchymal stem cells	miR-379	Therapy for metastatic breast cancer	[245]	
EVs from adipose tissue-mesenchymal stromal cells	miR-424-5p	Therapy for triple negative breast cancer	[356]	
Exosomes from HEK-293T cells	miR-497	Inhibit lung cancer growth and angiogenesis	[357]	
Exosomes from CRC cells	miR-567	Reverse chemoresistance to Trastuzumab in breast cancer	[358]	
EVs from HEK-293T cells	miR-1252-5p	Downregulation of heparanase to enhance the chemosensitivity to Bortezomib in multiple myeloma	[359]	
EVs from HEK-293T cells	miRNA-21	Myocardial infarction treatment	[360]	
Exosomes from breast cancer	miRNA-126	Inhibit the formation of lung cancer metastasis	[361]	
EVs from glioblastoma stem-like cells	miRNA-139	Downregulation of glioblastoma	[362]	
Exosomes from mesenchymal stem cells	miRNA-584-5p	Gliomas treatment	[363]	
Exosomes 293F cells	mRNA	SARS-CoV-2 vaccine	[364]	
Exosomes from HEK-293T cells	Catalase mRNA	Attenuated neurotoxicity and neuroinflammation in Parkinson’s disease	[365]	
EVs from HEK-293T cells	Cytosine deaminase fused to uracil phosphoribosyltransferase mRNA	Glioblastoma treatment	[366]	
EVs from HEK-293T cells	HChrR6 mRNA	Convert CNOB into MCHB for the treatment of cancers	[367]	
Exosomes from mesenchymal stem cells, dendritic cells or HEK-293T cells	PTEN mRNA	Restore tumor-suppressor function in PTEN deficient gliomas	[368]	
EVs from non-pigmented ciliary epithelium cells	anti-fibrotic (SMAD7) siRNA	Lower intraocular pressure in primary open-angle glaucoma	[369]	
Exosomes from autologous breast cancer cells	Cationic bovine serum albumin conjugated siS100A4	Suppress postoperative breast cancer metastasis	[370]	
EVs from murine neuroblastoma cell line and dendritic cells	Cholesterol-conjugated siRNAs	Human antigen R silencing for cancer treatment	[334]	
Exosomes from HEK-293T cells	c-Met siRNA	Reverse chemoresistance to cisplatin in gastric cancer	[371]	
Exosomes from HEK-293T cells	Hepatocyte growth factor (HGF) siRNA	Inhibitory effect on tumor growth and angiogenesis in gastric cancer	[372]	
EVs from mesenchymal stem cells derived from umbilical cord Wharton’s jelly	Hydrophobically modified asymmetric siRNAs conjugated with cholesterol	Huntingtin silencing in neurons	[333]	
Exosomes from glioblastoma cells	[373]	
Exosomes from human neuroblastoma cells	Heat shock protein-27 (HSP27) siRNA	Decrease of cell differentiation toward mature neuron in neuroblastoma	[374]	
Exosomes from urine-derived induced pluripotent stem cells	ICAM-1 siRNA	Alleviating inflammation of pulmonary microvascular endothelial cells	[375]	
Exosomes from HEK-293T cells	KRAS siRNA	Inhibition of tumor growth	[376]	
EVs from astrocytes	LincRNA-Cox2 siRNA	Lipopolysaccharideinduced microglial proliferation for treatment of CNS disorders	[377]	
Exosomes from mesenchymal stem cells	PTEN siRNA	Promote recovery for spinal cord injury individuals	[378]	
EVs from red blood cells	P65 and Snai1 siRNA	Inhibit renal inflammation and fibrosis for acute kidney injury treatment	[379]	
EVs from HEK-293T cells	RAGE siRNA	Attenuated inflammation in myocarditis	[380]	
Exosomes from bone-marrow-derived mesenchymal stem cells	siGRP78	Suppress Sorafenib resistance in hepatocellular carcinoma	[381]	
Exosomes from bovine milk	siKRAS	Lung tumor treatment	[382]	
EVs from different cell lines	siRNA	Reducing the therapeutic dose of siRNA for different pathologies	[383]	
EVs from human umbilical cord mesenchymal stem cells	siRNA-ELFN1-AS1	Inhibit colon adenocarcinoma cells proliferation	[384]	
Exosomes from normal human foreskin fibroblast	siRNA or short hairpin RNA specific to oncogenic KrasG12D	Pancreatic ductal adenocarcinoma treatment	[385]	
Exosomes from HEK-293T cells	Transient receptor potential polycystic 2 (TRPP2) siRNA	Reduce the epithelial-mesenchymal transition in pharyngeal squamous carcinoma	[386]	
Exosomes from brain endothelial bEND.3 cells	Vascular endothelial growth factor (VEGF) siRNA	Knockdown of VEGF in brain cancer cells	[387]	
Exosomes from HEK-293T cells	Different viral products including Ebola Virus VP24, VP40 and NP, Influenza Virus NP, Crimean–Congo Hemorrhagic Fever NP, West Nile Virus NS3, and Hepatitis C Virus NS3	Exosomes-based vaccines	[388]	

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Mullard A. 2020 fda drug approvals Nat. Rev. Drug Discov. 2021 20 85 90 10.1038/d41573-021-00002-0 33402709
2. Deng Y. Zhang X. Shen H. He Q. Wu Z. Liao W. Yuan M. Application of the nano-drug delivery system in treatment of cardiovascular diseases Front. Bioeng. Biotechnol. 2020 7 489 10.3389/fbioe.2019.00489 32083068
3. Edis Z. Wang J. Waqas M.K. Ijaz M. Ijaz M. Nanocarriers-mediated drug delivery systems for anticancer agents: An overview and perspectives Int. J. Nanomed. 2021 16 1313 1330 10.2147/IJN.S289443
4. Wilczewska A.Z. Niemirowicz K. Markiewicz K.H. Car H. Nanoparticles as drug delivery systems Pharmacol. Rep. 2012 64 1020 1037 10.1016/S1734-1140(12)70901-5 23238461
5. Ruzycka-Ayoush M. Kowalik P. Kowalczyk A. Bujak P. Nowicka A.M. Wojewodzka M. Kruszewski M. Grudzinski I.P. Quantum dots as targeted doxorubicin drug delivery nanosystems in human lung cancer cells Cancer Nanotechnol. 2021 12 8 10.1186/s12645-021-00077-9
6. Shehata T.M. Ibrahim M.M. Elsewedy H.S. Curcumin niosomes prepared from proniosomal gels: In vitro skin permeability, kinetic and in vivo studies Polymers 2021 13 791 10.3390/polym13050791 33806659
7. Ge X. Wei M. He S. Yuan W.E. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery Pharmaceutics 2019 11 55 10.3390/pharmaceutics11020055
8. Vashist S. Kaushik J. Sunil B.K. A review article: Proniosomes PharmaTutor 2015 3 25 30
9. Khatoon M. Shah K.U. Din F.U. Shah S.U. Rehman A.U. Dilawar N. Khan A.N. Proniosomes derived niosomes: Recent advancements in drug delivery and targeting Drug Deliv. 2017 24 56 69 10.1080/10717544.2017.1384520 29130758
10. Li D. Wu Z. Martini N. Wen J. Advanced carrier systems in cosmetics and cosmeceuticals: A review J. Cosmet. Sci. 2011 62 549 563 22682399
11. Handjani-Vila R.M. Ribier A. Rondot B. Vanlerberghie G. Dispersions of lamellar phases of non-ionic lipids in cosmetic products Int. J. Cosmet. Sci. 1979 1 303 314 10.1111/j.1467-2494.1979.tb00224.x 19467076
12. Sammour R.M.F. Taher M. Chatterjee B. Shahiwala A. Mahmood S. Optimization of aceclofenac proniosomes by using different carriers, part 1: Development and characterization Pharmaceutics 2019 11 350 10.3390/pharmaceutics11070350
13. Shehata T.M. Abdallah M.H. Ibrahim M.M. Proniosomal oral tablets for controlled delivery and enhanced pharmacokinetic properties of acemetacin AAPS PharmSciTech 2015 16 375 383 10.1208/s12249-014-0233-5 25319057
14. Ramkanth S. Chetty C.M. Sudhakar Y. Thiruvengadarajan V.S. Anitha P. Gopinath C. Development, characterization & invivo evaluation of proniosomal based transdermal delivery system of atenolol Future J. Pharm. Sci. 2018 4 80 87
15. Eltellawy Y.A. El-Kayal M. Abdel-Rahman R.F. Salah S. Shaker D.S. Optimization of transdermal atorvastatin calcium—loaded proniosomes: Restoring lipid profile and alleviating hepatotoxicity in poloxamer 407-induced hyperlipidemia Int. J. Pharm. 2021 593 120163 10.1016/j.ijpharm.2020.120163 33309831
16. Mehta M. Dureja H. Garg M. Development and optimization of boswellic acid-loaded proniosomal gel Drug Deliv. 2016 23 3072 3081 10.3109/10717544.2016.1149744 26953869
17. Aboumanei M.H. Mahmoud A.F. Design and development of a proniosomal transdermal drug delivery system of caffeine for management of migraine: In vitro characterization, 131i-radiolabeling and in vivo biodistribution studies Process. Biochem. 2020 97 201 212 10.1016/j.procbio.2020.07.018
18. Nemr A.A. El-Mahrouk G.M. Badie H.A. Development and evaluation of proniosomes to enhance the transdermal delivery of cilostazole and to ensure the safety of its application Drug Dev. Ind. Pharm. 2021 47 403 415 10.1080/03639045.2021.1890111 33625936
19. Tareen F.K. Shah K.U. Ahmad N. Asim.ur.Rehman Shah S.U. Ullah N. Proniosomes as a carrier system for transdermal delivery of clozapine Drug Dev. Ind. Pharm. 2020 46 946 954 10.1080/03639045.2020.1764020
20. Aboali F.A. Habib D.A. Elbedaiwy H.M. Farid R.M. Curcumin-loaded proniosomal gel as a biofreindly alternative for treatment of ocular inflammation: In-vitro and in-vivo assessment Int. J. Pharm. 2020 589 119835 10.1016/j.ijpharm.2020.119835 32890654
21. Liu H. Tu L. Zhou Y. Dang Z. Wang L. Du J. Feng J. Hu K. Improved bioavailability and antitumor effect of docetaxel by tpgs modified proniosomes: In vitro and in vivo evaluations Sci. Rep. 2017 7 43372 10.1038/srep43372 28266539
22. Mokale V.J. Patil H.I. Patil A.P. Shirude P.R. Naik J.B. Formulation and optimisation of famotidine proniosomes: An in vitro and ex vivo study J. Exp. Nanosci. 2016 11 97 110 10.1080/17458080.2015.1030711
23. Verma P. Prajapati S.K. Yadav R. Senyschyn D. Shea P.R. Trevaskis N.L. Single intravenous dose of novel flurbiprofen-loaded proniosome formulations provides prolonged systemic exposure and anti-inflammatory effect Mol. Pharm. 2016 13 3688 3699 10.1021/acs.molpharmaceut.6b00504 27632682
24. Kumar S. Jain P. Pandey N. Saxena G. Comparative study of proniosomal drug delivery system of flurbiprofen J. Chem. Pharm. Res. 2016 8 222 228
25. Wagh V.D. Deshmukh O.J. Itraconazole niosomes drug delivery system and its antimycotic activity against candida albicans ISRN Pharm. 2012 2012 653465 10.5402/2012/653465 23378932
26. Soliman S.M. Abdelmalak N.S. El-Gazayerly O.N. Abdelaziz N. Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: Optimization using 2(3) factorial design and in vivo evaluation in rabbits Drug Deliv. 2016 23 1608 1622 10.3109/10717544.2015.1132797 26758033
27. Khudair N. Agouni A. Elrayess M.A. Najlah M. Younes H.M. Elhissi A. Letrozole-loaded nonionic surfactant vesicles prepared via a slurry-based proniosome technology: Formulation development and characterization J. Drug Deliv. Sci. Technol. 2020 58 101721 10.1016/j.jddst.2020.101721
28. Gadela R. Sai G. Sunayana N. Soujanya G. Charan K. Formulation and evaluation of lignocaine hydrochloride proniosomes loaded orabase for dental anaesthesia J. Drug Deliv. Ther. 2021 11 27 34
29. Khalil R.M. Abdelbary G.A. Basha M. Awad G.E. El-Hashemy H.A. Design and evaluation of proniosomes as a carrier for ocular delivery of lomefloxacin hcl J. Liposome Res. 2017 27 118 129 10.3109/08982104.2016.1167737 27079800
30. Madan J.R. Ghuge N.P. Dua K. Formulation and evaluation of proniosomes containing lornoxicam Drug Deliv. Transl. Res. 2016 6 511 518 10.1007/s13346-016-0296-9 27255375
31. Shah H. Nair A.B. Shah J. Bharadia P. Al-Dhubiab B.E. Proniosomal gel for transdermal delivery of lornoxicam: Optimization using factorial design and in vivo evaluation in rats Daru 2019 27 59 70 10.1007/s40199-019-00242-x 30701460
32. Shah H. Nair A.B. Shah J. Jacob S. Bharadia P. Haroun M. Proniosomal vesicles as an effective strategy to optimize naproxen transdermal delivery J. Drug Deliv. Sci. Technol. 2021 63 102479 10.1016/j.jddst.2021.102479
33. Abdelbary G.A. Aburahma M.H. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain J. Liposome Res. 2015 25 107 121 10.3109/08982104.2014.941861 25058447
34. Madni A. Rahim M.A. Mahmood M.A. Jabar A. Rehman M. Shah H. Khan A. Tahir N. Shah A. Enhancement of dissolution and skin permeability of pentazocine by proniosomes and niosomal gel AAPS PharmSciTech 2018 19 1544 1553 10.1208/s12249-018-0967-6 29470828
35. Shruthi P.A. Pushpadass H.A. Franklin M.E.E. Battula S.N. Laxmana Naik N. Resveratrol-loaded proniosomes: Formulation, characterization and fortification LWT 2020 134 110127 10.1016/j.lwt.2020.110127
36. Sambhakar S. Paliwal S. Sharma S. Singh B. Formulation of risperidone loaded proniosomes for effective transdermal delivery: An in-vitro and in-vivo study Bull. Fac. Pharm. Cairo Univ. 2017 55 239 247 10.1016/j.bfopcu.2017.09.003
37. Shah J. Nair A.B. Shah H. Jacob S. Shehata T.M. Morsy M.A. Enhancement in antinociceptive and anti-inflammatory effects of tramadol by transdermal proniosome gel Asian J. Pharm. Sci. 2020 15 786 796 10.1016/j.ajps.2019.05.001 33363633
38. Gamal A. Saeed H. Sayed O.M. Kharshoum R.M. Salem H.F. Proniosomal microcarriers: Impact of constituents on the physicochemical properties of proniosomes as a new approach to enhance inhalation efficiency of dry powder inhalers AAPS PharmSciTech 2020 21 156 10.1208/s12249-020-01705-0 32449087
39. Mohsen A.M. Salama A. Kassem A.A. Development of acetazolamide loaded bilosomes for improved ocular delivery: Preparation, characterization and in vivo evaluation J. Drug Deliv. Sci. Technol. 2020 59 101910 10.1016/j.jddst.2020.101910
40. Abdelmonem R. Elhabal S.F. Abdelmalak N.S. El-Nabarawi M.A. Teaima M.H. Formulation and characterization of acetazolamide/carvedilol niosomal gel for glaucoma treatment: In vitro, and in vivo study Pharmaceutics 2021 13 221 10.3390/pharmaceutics13020221 33562785
41. Jacob S. Nair A.B. Al-Dhubiab B.E. Preparation and evaluation of niosome gel containing acyclovir for enhanced dermal deposition J. Liposome Res. 2017 27 283 292 10.1080/08982104.2016.1224897 27558522
42. Monavari S.H. Mirzaei Parsa M.J. Bolouri B. Ebrahimi S.A. Ataei-Pirkooh A. The inhibitory effect of acyclovir loaded nano-niosomes against herpes simplex virus type-1 in cell culture Med. J. Islam Repub. Iran. 2014 28 99 25664300
43. Allam A. Elsabahy M. El Badry M. Eleraky N.E. Betaxolol-loaded niosomes integrated within ph-sensitive in situ forming gel for management of glaucoma Int. J. Pharm. 2021 598 120380 10.1016/j.ijpharm.2021.120380 33609725
44. Barani M. Mirzaei M. Torkzadeh-Mahani M. Adeli-sardou M. Evaluation of carum-loaded niosomes on breast cancer cells:Physicochemical properties, in vitro cytotoxicity, flow cytometric, DNA fragmentation and cell migration assay Sci. Rep. 2019 9 7139 10.1038/s41598-019-43755-w 31073144
45. Taymouri S. Varshosaz J. Effect of different types of surfactants on the physical properties and stability of carvedilol nano-niosomes Adv. Biomed. Res. 2016 5 48 27110545
46. Arzani G. Haeri A. Daeihamed M. Bakhtiari-Kaboutaraki H. Dadashzadeh S. Niosomal carriers enhance oral bioavailability of carvedilol: Effects of bile salt-enriched vesicles and carrier surface charge Int. J. Nanomed. 2015 10 4797 4813
47. Ghafelehbashi R. Akbarzadeh I. Tavakkoli Yaraki M. Lajevardi A. Fatemizadeh M. Heidarpoor Saremi L. Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes Int. J. Pharm. 2019 569 118580 10.1016/j.ijpharm.2019.118580 31374239
48. Kashef M.T. Saleh N.M. Assar N.H. Ramadan M.A. The antimicrobial activity of ciprofloxacin-loaded niosomes against ciprofloxacin-resistant and biofilm-forming staphylococcus aureus Infect. Drug Resist. 2020 13 1619 1629 10.2147/IDR.S249628 32606813
49. Mirzaie A. Peirovi N. Akbarzadeh I. Moghtaderi M. Heidari F. Yeganeh F.E. Noorbazargan H. Mirzazadeh S. Bakhtiari R. Preparation and optimization of ciprofloxacin encapsulated niosomes: A new approach for enhanced antibacterial activity, biofilm inhibition and reduced antibiotic resistance in ciprofloxacin-resistant methicillin-resistance staphylococcus aureus Bioorganic Chem. 2020 103 104231 10.1016/j.bioorg.2020.104231
50. Akbari J. Saeedi M. Enayatifard R. Morteza-Semnani K. Hassan Hashemi S.M. Babaei A. Rahimnia S.M. Rostamkalaei S.S. Nokhodchi A. Curcumin niosomes (curcusomes) as an alternative to conventional vehicles: A potential for efficient dermal delivery J. Drug Deliv. Sci. Technol. 2020 60 102035 10.1016/j.jddst.2020.102035
51. Liu F.R. Jin H. Wang Y. Chen C. Li M. Mao S.J. Wang Q. Li H. Anti-cd123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia Drug Deliv. 2017 24 882 890 10.1080/10717544.2017.1333170 28574300
52. Hajizadeh M.R. Maleki H. Barani M. Fahmidehkar M.A. Mahmoodi M. Torkzadeh-Mahani M. In vitro cytotoxicity assay of d-limonene niosomes: An efficient nano-carrier for enhancing solubility of plant-extracted agents Res. Pharm. Sci. 2019 14 448 458 31798662
53. Tavano L. Vivacqua M. Carito V. Muzzalupo R. Caroleo M.C. Nicoletta F. Doxorubicin loaded magneto-niosomes for targeted drug delivery Colloids Surf. B Biointerfaces 2013 102 803 807 10.1016/j.colsurfb.2012.09.019 23107959
54. Tavano L. Muzzalupo R. Mauro L. Pellegrino M. Andò S. Picci N. Transferrin-conjugated pluronic niosomes as a new drug delivery system for anticancer therapy Langmuir 2013 29 12638 12646 10.1021/la4021383 24040748
55. Barani M. Mirzaei M. Torkzadeh-Mahani M. Lohrasbi-Nejad A. Nematollahi M.H. A new formulation of hydrophobin-coated niosome as a drug carrier to cancer cells Mater. Sci. Eng. C 2020 113 110975 10.1016/j.msec.2020.110975
56. Pawar S. Shevalkar G. Vavia P. Glucosamine-anchored doxorubicin-loaded targeted nano-niosomes: Pharmacokinetic, toxicity and pharmacodynamic evaluation J. Drug Target. 2016 24 730 743 10.3109/1061186X.2016.1154560 26878084
57. Akbarzadeh I. Tavakkoli Yaraki M. Bourbour M. Noorbazargan H. Lajevardi A. Sadat Shilsar S.M. Heidari F. Mousavian S.M. Optimized doxycycline-loaded niosomal formulation for treatment of infection-associated prostate cancer: An in-vitro investigation J. Drug Deliv. Sci. Technol. 2020 57 101715 10.1016/j.jddst.2020.101715
58. Gugleva V. Titeva S. Rangelov S. Momekova D. Design and in vitro evaluation of doxycycline hyclate niosomes as a potential ocular delivery system Int. J. Pharm 2019 567 118431 10.1016/j.ijpharm.2019.06.022 31207279
59. Alam M.S. Ahad A. Abidin L. Aqil M. Mir S.R. Mujeeb M. Embelin-loaded oral niosomes ameliorate streptozotocin-induced diabetes in wistar rats Biomed. Pharm. 2018 97 1514 1520 10.1016/j.biopha.2017.11.073 29793314
60. Gupta M. Vaidya B. Mishra N. Vyas S.P. Effect of surfactants on the characteristics of fluconazole niosomes for enhanced cutaneous delivery Artif Cells Blood Substit. Immobil. Biotechnol. 2011 39 376 384 10.3109/10731199.2011.611476 21951195
61. El-Sayed M.M. Hussein A.K. Sarhan H.A. Mansour H.F. Flurbiprofen-loaded niosomes-in-gel system improves the ocular bioavailability of flurbiprofen in the aqueous humor Drug Dev. Ind. Pharm. 2017 43 902 910 10.1080/03639045.2016.1272120 27977311
62. Mohamad Saimi N.I. Salim N. Ahmad N. Abdulmalek E. Abdul Rahman M.B. Aerosolized niosome formulation containing gemcitabine and cisplatin for lung cancer treatment: Optimization, characterization and in vitro evaluation Pharmaceutics 2021 13 59 10.3390/pharmaceutics13010059 33466428
63. Khan S. Akhtar M.U. Khan S. Javed F. Khan A.A. Nanoniosome-encapsulated levoflaxicin as an antibacterial agent against brucella J. Basic Microbiol. 2020 60 281 290 10.1002/jobm.201900454 31856360
64. Dandagi P. Naik V. Gadad A. Mastiholimath V. Shedbal S. Rangoli S. Kazi T. Formulation and evaluation of linezolid niosomal gel for topical drug delivery World J. Pharm. Res. 2020 9 674 690
65. Demirbolat G.M. Aktas E. Coskun G.P. Erdogan O. Cevik O. New approach to formulate methotrexate-loaded niosomes: In vitro characterization and cellular effectiveness J. Pharm. Innov. 2021 1 1 16 10.1007/s12247-021-09539-4
66. Al-Mahallawi A.M. Fares A.R. Abd-Elsalam W.H. Enhanced permeation of methotrexate via loading into ultra-permeable niosomal vesicles: Fabrication, statistical optimization, ex vivo studies, and in vivo skin deposition and tolerability AAPS PharmSciTech 2019 20 171 10.1208/s12249-019-1380-5 31004239
67. Muzzalupo R. Tavano L. La Mesa C. Alkyl glucopyranoside-based niosomes containing methotrexate for pharmaceutical applications: Evaluation of physico-chemical and biological properties Int. J. Pharm. 2013 458 224 229 10.1016/j.ijpharm.2013.09.011 24060370
68. Hasan A.A. Madkor H. Wageh S. Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system Drug Deliv. 2013 20 120 126 10.3109/10717544.2013.779332 23651102
69. Wongsuwan N. Dwivedi A. Tancharoen S. Nasongkla N. Development of dental implant coating with minocycline-loaded niosome for antibacterial application J. Drug Deliv. Sci. Technol. 2020 56 101555 10.1016/j.jddst.2020.101555
70. Sohrabi S. Haeri A. Mahboubi A. Mortazavi A. Dadashzadeh S. Chitosan gel-embedded moxifloxacin niosomes: An efficient antimicrobial hybrid system for burn infection Int. J. Biol. Macromol. 2016 85 625 633 10.1016/j.ijbiomac.2016.01.013 26794314
71. Mehta S.K. Jindal N. Tyloxapol niosomes as prospective drug delivery module for antiretroviral drug nevirapine AAPS Pharm. Sci. Tech. 2015 16 67 75 10.1208/s12249-014-0183-y
72. Bragagni M. Mennini N. Furlanetto S. Orlandini S. Ghelardini C. Mura P. Development and characterization of functionalized niosomes for brain targeting of dynorphin-b Eur. J. Pharm. Biopharm. 2014 87 73 79 10.1016/j.ejpb.2014.01.006 24462793
73. Naseroleslami M. Niri N.M. Akbarzade I. Sharifi M. Aboutaleb N. Simvastatin-loaded nano-niosomes confer cardioprotection against myocardial ischemia/reperfusion injury Drug Deliv. Transl. Res. 2021 1 10 10.1007/s13346-021-01019-z
74. Zidan A.S. Hosny K.M. Ahmed O.A. Fahmy U.A. Assessment of simvastatin niosomes for pediatric transdermal drug delivery Drug Deliv. 2016 23 1536 1549 10.3109/10717544.2014.980896 25386740
75. Salem H.F. Kharshoum R.M. El-Ela F.I.A. Abdellatif K.R.A. Evaluation and optimization of ph-responsive niosomes as a carrier for efficient treatment of breast cancer Drug Deliv. Transl. Res. 2018 8 633 644 10.1007/s13346-018-0499-3 29488171
76. Kulkarni P. Rawtani D. Application of box-behnken design in the preparation, optimization, and in vitro evaluation of self-assembly-based tamoxifen- and doxorubicin-loaded and dual drug-loaded niosomes for combinatorial breast cancer treatment J. Pharm. Sci. 2019 108 2643 2653 10.1016/j.xphs.2019.03.020 30905701
77. Yadavar-Nikravesh M.-S. Ahmadi S. Milani A. Akbarzadeh I. Khoobi M. Vahabpour R. Bolhassani A. Bakhshandeh H. Construction and characterization of a novel tenofovir-loaded pegylated niosome conjugated with tat peptide for evaluation of its cytotoxicity and anti-hiv effects Adv. Powder Technol. 2021 32 3161 3173 10.1016/j.apt.2021.05.047
78. Ramadan A.A. Eladawy S.A. El-Enin A.S.M.A. Hussein Z.M. Development and investigation of timolol maleate niosomal formulations for the treatment of glaucoma J. Pharm. Investig. 2020 50 59 70 10.1007/s40005-019-00427-1
79. Soni P.S.T. Non-ionic surfactant vesicles (niosomes) based novel ophthalmic formulation of timolol maleate J. Drug Deliv. Ther. 2017 7 59 61
80. Dubey A. Prabhu P. Development and investigation of niosomes of brimonidine tartrate and timolol maleate for the treatment of glaucoma Int. J. Pharm.Tech. Res. 2014 6 942 950
81. Hedayati Ch M. Abolhassani Targhi A. Shamsi F. Heidari F. Salehi Moghadam Z. Mirzaie A. Behdad R. Moghtaderi M. Akbarzadeh I. Niosome-encapsulated tobramycin reduced antibiotic resistance and enhanced antibacterial activity against multidrug-resistant clinical strains of pseudomonas aeruginosa J. Biomed. Mater. Res. Part. A 2021 109 966 980 10.1002/jbm.a.37086
82. Allam A. El-Mokhtar M.A. Elsabahy M. Vancomycin-loaded niosomes integrated within ph-sensitive in-situ forming gel for treatment of ocular infections while minimizing drug irritation J. Pharm. Pharm. 2019 71 1209 1221 10.1111/jphp.13106
83. Dwivedi A. Mazumder A. Nasongkla N. In vitro and in vivo biocompatibility of orthopedic bone plate nano-coated with vancomycin loaded niosomes J. Drug Deliv. Sci. Technol. 2019 52 215 223 10.1016/j.jddst.2019.04.018
84. Shinde A.J. Swami K.B. Tamboli F.A. More H.N. Design and development of zolmitriptan niosomal in situ nasal gel for the treatment of migrain Int. J. Res. Pharm. Sci. 2021 12 1861 1869 10.26452/ijrps.v12i3.4786
85. De A. Venkatesh N. Senthil M. Sanapalli B.K.R. Shanmugham R. Karri V. Smart niosomes of temozolomide for enhancement of brain targeting Nanobiomedicine 2018 5 1849543518805355 10.1177/1849543518805355 30344765
86. Ag Seleci D. Seleci M. Stahl F. Scheper T. Tumor homing and penetrating peptide-conjugated niosomes as multi-drug carriers for tumor-targeted drug delivery RSC Adv. 2017 7 33378 33384 10.1039/C7RA05071B
87. Rajput S. Puvvada N. Kumar B.N. Sarkar S. Konar S. Bharti R. Dey G. Mazumdar A. Pathak A. Fisher P.B. Overcoming akt induced therapeutic resistance in breast cancer through sirna and thymoquinone encapsulated multilamellar gold niosomes Mol. Pharm. 2015 12 4214 4225 10.1021/acs.molpharmaceut.5b00692 26505213
88. Rathee J. Kanwar R. Kaushik D. Salunke D.B. Mehta S.K. Niosomes as efficient drug delivery modules for encapsulation of toll-like receptor 7 agonists and ido-inhibitor Appl. Surf. Sci. 2020 505 144078 10.1016/j.apsusc.2019.144078
89. Attia N. Mashal M. Grijalvo S. Eritja R. Zárate J. Puras G. Pedraz J.L. Stem cell-based gene delivery mediated by cationic niosomes for bone regeneration Nanomedicine 2018 14 521 531 10.1016/j.nano.2017.11.005 29157978
90. García-Manrique P. Serrano-Pertierra E. Lozano-Andrés E. López-Martín S. Matos M. Gutiérrez G. Yáñez-Mó M. Blanco-López M.C. Selected tetraspanins functionalized niosomes as potential standards for exosome immunoassays Nanomaterials 2020 10 971 10.3390/nano10050971
91. Obeid M.A. Teeravatcharoenchai T. Connell D. Niwasabutra K. Hussain M. Carter K. Ferro V.A. Examination of the effect of niosome preparation methods in encapsulating model antigens on the vesicle characteristics and their ability to induce immune responses J. Liposome Res. 2021 31 195 202 10.1080/08982104.2020.1768110 32396752
92. Nematollahi M.H. Torkzadeh-Mahanai M. Pardakhty A. Ebrahimi Meimand H.A. Asadikaram G. Ternary complex of plasmid DNA with nls-mu-mu protein and cationic niosome for biocompatible and efficient gene delivery: A comparative study with protamine and lipofectamine Artif Cells Nanomed. Biotechnol. 2018 46 1781 1791 10.1080/21691401.2017.1392316 29081256
93. Mashal M. Attia N. Soto-Sánchez C. Martínez-Navarrete G. Fernández E. Puras G. Pedraz J.L. Non-viral vectors based on cationic niosomes as efficient gene delivery vehicles to central nervous system cells into the brain Int. J. Pharm. 2018 552 48 55 10.1016/j.ijpharm.2018.09.038 30244145
94. Pengnam S. Patrojanasophon P. Rojanarata T. Ngawhirunpat T. Yingyongnarongkul B.-E. Radchatawedchakoon W. Opanasopit P. A novel plier-like gemini cationic niosome for nucleic acid delivery J. Drug Deliv. Sci. Technol. 2019 52 325 333 10.1016/j.jddst.2019.04.032
95. Gallego I. Villate-Beitia I. Martínez-Navarrete G. Menéndez M. López-Méndez T. Soto-Sánchez C. Zárate J. Puras G. Fernández E. Pedraz J.L. Non-viral vectors based on cationic niosomes and minicircle DNA technology enhance gene delivery efficiency for biomedical applications in retinal disorders Nanomedicine 2019 17 308 318 10.1016/j.nano.2018.12.018 30790710
96. Pereira M.C. Pianella M. Wei D. Moshnikova A. Marianecci C. Carafa M. Andreev O.A. Reshetnyak Y.K. Ph-sensitive phlip(®) coated niosomes Mol. Membr. Biol. 2016 33 51 63 10.1080/09687688.2017.1342969 28792261
97. Pamornpathomkul B. Niyomtham N. Yingyongnarongkul B.E. Prasitpuriprecha C. Rojanarata T. Ngawhirunpat T. Opanasopit P. Cationic niosomes for enhanced skin immunization of plasmid DNA-encoding ovalbumin via hollow microneedles AAPS PharmSciTech 2018 19 481 488 10.1208/s12249-017-0855-5 28828737
98. Puras G. Mashal M. Zárate J. Agirre M. Ojeda E. Grijalvo S. Eritja R. Diaz-Tahoces A. Martínez Navarrete G. Avilés-Trigueros M. A novel cationic niosome formulation for gene delivery to the retina J. Control. Release 2014 174 27 36 10.1016/j.jconrel.2013.11.004 24231407
99. Gogoi H. Mani R. Bhatnagar R. A niosome formulation modulates the th1/th2 bias immune response in mice and also provides protection against anthrax spore challenge Int. J. Nanomed. 2018 13 7427 7440 10.2147/IJN.S153150
100. Yang C. Gao S. Song P. Dagnæs-Hansen F. Jakobsen M. Kjems J. Theranostic niosomes for efficient sirna/microrna delivery and activatable near-infrared fluorescent tracking of stem cells ACS Appl. Mater. Interfaces 2018 10 19494 19503 10.1021/acsami.8b05513 29767944
101. Obeid M.A. Alyamani H. Amawi H. Aljabali A.A.A. Rezigue M. Abdeljaber S.N. Ferro V.A. Sirna delivery to melanoma cells with cationic niosomes Methods Mol. Biol. 2021 2265 621 634 33704743
102. Pengnam S. Plianwong S. Patrojanasophon P. Radchatawedchakoon W. Yingyongnarongkul B.E. Opanasopit P. Charoensuksai P. Synergistic effect of doxorubicin and sirna-mediated silencing of mcl-1 using cationic niosomes against 3d mcf-7 spheroids Pharmaceutics 2021 13 550 10.3390/pharmaceutics13040550 33919902
103. Maurer V. Altin S. Ag Seleci D. Zarinwall A. Temel B. Vogt P.M. Strauß S. Stahl F. Scheper T. Bucan V. In-vitro application of magnetic hybrid niosomes: Targeted sirna-delivery for enhanced breast cancer therapy Pharmaceutics 2021 13 394 10.3390/pharmaceutics13030394 33809700
104. Hemati M. Haghiralsadat F. Yazdian F. Jafari F. Moradi A. Malekpour-Dehkordi Z. Development and characterization of a novel cationic pegylated niosome-encapsulated forms of doxorubicin, quercetin and sirna for the treatment of cancer by using combination therapy Artif. Cells Nanomed. Biotechnol. 2019 47 1295 1311 10.1080/21691401.2018.1489271 30033768
105. Slavin Y.N. Ivanova K. Tang W.-l. Tzanov T. Li S.-d. Bach H. Targeting intracellular mycobacteria using nanosized niosomes loaded with antibacterial agents Nanomaterials 2021 11 1984 10.3390/nano11081984 34443815
106. Targhi A.A. Moammeri A. Jamshidifar E. Abbaspour K. Sadeghi S. Lamakani L. Akbarzadeh I. Synergistic effect of curcumin-cu and curcumin-ag nanoparticle loaded niosome: Enhanced antibacterial and anti-biofilm activities Bioorganic Chem. 2021 115 105116 10.1016/j.bioorg.2021.105116 34333420
107. Barani M. Nematollahi M.H. Zaboli M. Mirzaei M. Torkzadeh-Mahani M. Pardakhty A. Karam G.A. In silico and in vitro study of magnetic niosomes for gene delivery: The effect of ergosterol and cholesterol Mater. Sci. Eng. C Mater. Biol. Appl. 2019 94 234 246 10.1016/j.msec.2018.09.026 30423705
108. Touitou E. Dayan N. Bergelson L. Godin B. Eliaz M. Ethosomes—Novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties J. Control. Release 2000 65 403 418 10.1016/S0168-3659(99)00222-9 10699298
109. Lu J. Guo T. Fan Y. Li Z. He Z. Yin S. Feng N. Recent developments in the principles, modification and application prospects of functionalized ethosomes for topical delivery Curr. Drug Deliv. 2021 18 570 582 10.2174/1567201817666200826093102 32851961
110. Zhang Z. Chen Y. Xu H. Wo Y. Zhang Z. Liu Y. Su W. Cui D. Zhang Y. 5-aminolevulinic acid loaded ethosomal vesicles with high entrapment efficiency for in vitro topical transdermal delivery and photodynamic therapy of hypertrophic scars Nanoscale 2016 8 19270 19279 10.1039/C6NR06872C 27830857
111. Khan N.R. Wong T.W. Microwave-aided skin drug penetration and retention of 5-fluorouracil-loaded ethosomes Expert Opin. Drug Deliv. 2016 13 1209 1219 10.1080/17425247.2016.1193152 27212391
112. Khan N.R. Wong T.W. 5-fluorouracil ethosomes—Skin deposition and melanoma permeation synergism with microwave Artif. Cells Nanomed. Biotechnol. 2018 46 568 577 10.1080/21691401.2018.1431650 29378453
113. El-Shenawy A.A. Mahmoud R.A. Mahmoud E.A. Mohamed M.S. Int.ranasal in situ gel of apixaban-loaded nanoethosomes: Preparation, optimization, and in vivo evaluation AAPS PharmSciTech 2021 22 147 10.1208/s12249-021-02020-y 33948767
114. Apriani E.F. Rosana Y. Iskandarsyah I. Formulation, characterization, and in vitro testing of azelaic acid ethosome-based cream against propionibacterium acnes for the treatment of acne J. Adv. Pharm. Technol. Res. 2019 10 75 80 31041186
115. Mistry A. Ravikumar P. Development and evaluation of azelaic acid based ethosomes for topical delivery for the treatment of acne Indian J. Pharm. Educ. Res. 2016 50 S232 S243 10.5530/ijper.50.3.34
116. Hallan S.S. Sguizzato M. Mariani P. Cortesi R. Huang N. Simelière F. Marchetti N. Drechsler M. Ruzgas T. Esposito E. Design and characterization of ethosomes for transdermal delivery of caffeic acid Pharmaceutics 2020 12 740 10.3390/pharmaceutics12080740 32781717
117. Guo T. Lu J. Fan Y. Zhang Y. Yin S. Sha X. Feng N. Tpgs assists the percutaneous administration of curcumin and glycyrrhetinic acid coloaded functionalized ethosomes for the synergistic treatment of psoriasis Int. J. Pharm. 2021 604 120762 10.1016/j.ijpharm.2021.120762 34082000
118. Zhang Y. Xia Q. Li Y. He Z. Li Z. Guo T. Wu Z. Feng N. Cd44 assists the topical anti-psoriatic efficacy of curcumin-loaded hyaluronan-modified ethosomes: A new strategy for clustering drug in inflammatory skin Theranostics 2019 9 48 64 10.7150/thno.29715 30662553
119. Ma L. Wang X. Wu J. Zhang D. Zhang L. Song X. Hong H. He C. Mo X. Wu S. Polyethylenimine and sodium cholate-modified ethosomes complex as multidrug carriers for the treatment of melanoma through transdermal delivery Nanomedicine 2019 14 2395 2408 10.2217/nnm-2018-0398 31456475
120. Apolinário A.C. Hauschke L. Nunes J.R. Lourenço F.R. Lopes L.B. Design of multifunctional ethosomes for topical fenretinide delivery and breast cancer chemoprevention Colloids Surf. A Physicochem. Eng. Asp. 2021 623 126745 10.1016/j.colsurfa.2021.126745
121. Nasr S. Rady M. Gomaa I. Syrovets T. Simmet T. Fayad W. Abdel-Kader M. Ethosomes and lipid-coated chitosan nanocarriers for skin delivery of a chlorophyll derivative: A potential treatment of squamous cell carcinoma by photodynamic therapy Int. J. Pharm. 2019 568 118528 10.1016/j.ijpharm.2019.118528 31323373
122. Moolakkadath T. Aqil M. Ahad A. Imam S.S. Praveen A. Sultana Y. Mujeeb M. Iqbal Z. Fisetin loaded binary ethosomes for management of skin cancer by dermal application on uv exposed mice Int. J. Pharm. 2019 560 78 91 10.1016/j.ijpharm.2019.01.067 30742987
123. Paliwal S. Tilak A. Sharma J. Dave V. Sharma S. Yadav R. Patel S. Verma K. Tak K. Flurbiprofen loaded ethosomes—Transdermal delivery of anti-inflammatory effect in rat model Lipids Health Dis. 2019 18 133 10.1186/s12944-019-1064-x 31170970
124. Marto J. Vitor C. Guerreiro A. Severino C. Eleutério C. Ascenso A. Simões S. Ethosomes for enhanced skin delivery of griseofulvin Colloids Surf. B Biointerfaces 2016 146 616 623 10.1016/j.colsurfb.2016.07.021 27429295
125. Xie J. Ji Y. Xue W. Ma D. Hu Y. Hyaluronic acid-containing ethosomes as a potential carrier for transdermal drug delivery Colloids Surf. B Biointerfaces 2018 172 323 329 10.1016/j.colsurfb.2018.08.061 30176512
126. Zhang Y. Ng W. Hu J. Mussa S.S. Ge Y. Xu H. Formulation and in vitro stability evaluation of ethosomal carbomer hydrogel for transdermal vaccine delivery Colloids Surf. B Biointerfaces 2018 163 184 191 10.1016/j.colsurfb.2017.12.031 29294420
127. Sakdiset P. Amnuaikit T. Pichayakorn W. Pinsuwan S. Formulation development of ethosomes containing indomethacin for transdermal delivery J. Drug Deliv. Sci. Technol. 2019 52 760 768 10.1016/j.jddst.2019.05.048
128. Elsayed M.M.A. Okda T.M. Atwa G.M.K. Omran G.A. Abd Elbaky A.E. Ramadan A.E.H. Design and optimization of orally administered luteolin nanoethosomes to enhance its anti-tumor activity against hepatocellular carcinoma Pharmaceutics 2021 13 648 10.3390/pharmaceutics13050648 34063274
129. Chandra A. Aggarwal G. Manchanda S. Narula A. Development of topical gel of methotrexate incorporated ethosomes and salicylic acid for the treatment of psoriasis Pharm. Nanotechnol. 2019 7 362 374 10.2174/2211738507666190906123643 31490769
130. Garg B.J. Garg N.K. Beg S. Singh B. Katare O.P. Nanosized ethosomes-based hydrogel formulations of methoxsalen for enhanced topical delivery against vitiligo: Formulation optimization, in vitro evaluation and preclinical assessment J. Drug Target. 2016 24 233 246 10.3109/1061186X.2015.1070855 26267289
131. Ma H. Guo D. Fan Y. Wang J. Cheng J. Zhang X. Paeonol-loaded ethosomes as transdermal delivery carriers: Design, preparation and evaluation Molecules 2018 23 1756 10.3390/molecules23071756 30018278
132. Cui Y. Mo Y. Zhang Q. Tian W. Xue Y. Bai J. Du S. Microneedle-assisted percutaneous delivery of paeoniflorin-loaded ethosomes Molecules 2018 23 3371 10.3390/molecules23123371
133. Limsuwan T. Boonme P. Khongkow P. Amnuaikit T. Ethosomes of phenylethyl resorcinol as vesicular delivery system for skin lightening applications BioMed. Res. Int. 2017 2017 8310979 10.1155/2017/8310979 28804723
134. Arora D. Nanda S. Quality by design driven development of resveratrol loaded ethosomal hydrogel for improved dermatological benefits via enhanced skin permeation and retention Int. J. Pharm. 2019 567 118448 10.1016/j.ijpharm.2019.118448 31226472
135. Salem H.F. Kharshoum R.M. Awad S.M. Ahmed Mostafa M. Abou-Taleb H.A. Tailoring of retinyl palmitate-based ethosomal hydrogel as a novel nanoplatform for acne vulgaris management: Fabrication, optimization, and clinical evaluation employing a split-face comparative study Int. J. Nanomed. 2021 16 4251 4276 10.2147/IJN.S301597
136. Cristiano M.C. Froiio F. Spaccapelo R. Mancuso A. Nisticò S.P. Udongo B.P. Fresta M. Paolino D. Sulforaphane-loaded ultradeformable vesicles as a potential natural nanomedicine for the treatment of skin cancer diseases Pharmaceutics 2019 12 6 10.3390/pharmaceutics12010006
137. Iizhar S.A. Syed I.A. Satar R. Ansari S.A. In vitro assessment of pharmaceutical potential of ethosomes entrapped with terbinafine hydrochloride J. Adv. Res. 2016 7 453 461 10.1016/j.jare.2016.03.003 27222750
138. Kausar H. Mujeeb M. Ahad A. Moolakkadath T. Aqil M. Ahmad A. Akhter M.H. Optimization of ethosomes for topical thymoquinone delivery for the treatment of skin acne J. Drug Deliv. Sci. Technol. 2019 49 177 187 10.1016/j.jddst.2018.11.016
139. Fu X. Shi Y. Wang H. Zhao X. Sun Q. Huang Y. Qi T. Lin G. Ethosomal gel for improving transdermal delivery of thymosin β-4 Int. J. Nanomed. 2019 14 9275 9284 10.2147/IJN.S228863
140. Venkatesh D. Kalyani K. Tulasi K. Priyanka V. Ali S.K.A. Kiran H.C. Transfersomes: A novel technique for transdermal drug delivery J. Drug Deliv. Ther. 2019 9 279 285
141. Benson H.A. Transfersomes for transdermal drug delivery Expert Opin. Drug Deliv. 2006 3 727 737 10.1517/17425247.3.6.727 17076595
142. Jiang T. Wang T. Li T. Ma Y. Shen S. He B. Mo R. Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma ACS Nano 2018 12 9693 9701 10.1021/acsnano.8b03800 30183253
143. Opatha S.A.T. Titapiwatanakun V. Chutoprapat R. Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery Pharmaceutics 2020 12 855 10.3390/pharmaceutics12090855
144. Pandey A. Role of surfactants as penetration enhancer in transdermal drug delivery system J. Mol. Pharm. Org. Process. Res. 2014 2 2 7 10.4172/2329-9053.1000113
145. Dudhipala N. Phasha Mohammed R. Adel Ali Youssef A. Banala N. Effect of lipid and edge activator concentration on development of aceclofenac-loaded transfersomes gel for transdermal application: In vitro and ex vivo skin permeation Drug Dev. Ind. Pharm. 2020 46 1334 1344 10.1080/03639045.2020.1788069 32598194
146. Manconi M. Manca M.L. Caddeo C. Valenti D. Cencetti C. Diez-Sales O. Nacher A. Mir-Palomo S. Terencio M.C. Demurtas D. Nanodesign of new self-assembling core-shell gellan-transfersomes loading baicalin and in vivo evaluation of repair response in skin Nanomedicine 2018 14 569 579 10.1016/j.nano.2017.12.001 29248674
147. Chen M. Shamim M.A. Shahid A. Yeung S. Andresen B.T. Wang J. Nekkanti V. Meyskens F.L. Jr. Kelly K.M. Huang Y. Topical delivery of carvedilol loaded nano-transfersomes for skin cancer chemoprevention Pharmaceutics 2020 12 1151 10.3390/pharmaceutics12121151
148. Khatoon K. Rizwanullah M. Amin S. Mir S.R. Akhter S. Cilnidipine loaded transfersomes for transdermal application: Formulation optimization, in-vitro and in-vivo study J. Drug Deliv. Sci. Technol. 2019 54 101303 10.1016/j.jddst.2019.101303
149. El-Gizawy S.A. Nouh A. Saber S. Kira A.Y. Deferoxamine-loaded transfersomes accelerates healing of pressure ulcers in streptozotocin-induced diabetic rats J. Drug Deliv. Sci. Technol. 2020 58 101732 10.1016/j.jddst.2020.101732
150. Luiz M.T. Viegas J.S.R. Abriata J.P. Tofani L.B. Vaidergorn M.d.M. Emery F.d.S. Chorilli M. Marchetti J.M. Docetaxel-loaded folate-modified tpgs-transfersomes for glioblastoma multiforme treatment Mater. Sci. Eng. C 2021 124 112033 10.1016/j.msec.2021.112033
151. Avadhani K.S. Manikkath J. Tiwari M. Chandrasekhar M. Godavarthi A. Vidya S.M. Hariharapura R.C. Kalthur G. Udupa N. Mutalik S. Skin delivery of epigallocatechin-3-gallate (egcg) and hyaluronic acid loaded nano-transfersomes for antioxidant and anti-aging effects in uv radiation induced skin damage Drug Deliv. 2017 24 61 74 10.1080/10717544.2016.1228718 28155509
152. Ahad A. Al-Saleh A.A. Al-Mohizea A.M. Al-Jenoobi F.I. Raish M. Yassin A.E.B. Alam M.A. Formulation and characterization of phospholipon 90 g and tween 80 based transfersomes for transdermal delivery of eprosartan mesylate Pharm. Dev. Technol. 2018 23 787 793 10.1080/10837450.2017.1330345 28504046
153. Langasco R. Fancello S. Rassu G. Cossu M. Cavalli R. Galleri G. Giunchedi P. Migheli R. Gavini E. Increasing protective activity of genistein by loading into transfersomes: A new potential adjuvant in the oxidative stress-related neurodegenerative diseases? Phytomedicine 2019 52 23 31 10.1016/j.phymed.2018.09.207 30599903
154. Balata G.F. Faisal M.M. Elghamry H.A. Sabry S.A. Preparation and characterization of ivabradine hcl transfersomes for enhanced transdermal delivery J. Drug Deliv. Sci. Technol. 2020 60 101921 10.1016/j.jddst.2020.101921
155. Allaw M. Pleguezuelos-Villa M. Manca M.L. Caddeo C. Aroffu M. Nacher A. Diez-Sales O. Saurí A.R. Ferrer E.E. Fadda A.M. Innovative strategies to treat skin wounds with mangiferin: Fabrication of transfersomes modified with glycols and mucin Nanomedicine 2020 15 1671 1685 10.2217/nnm-2020-0116 32677507
156. Janga K.Y. Tatke A. Dudhipala N. Balguri S.P. Ibrahim M.M. Maria D.N. Jablonski M.M. Majumdar S. Gellan gum based sol-to-gel transforming system of natamycin transfersomes improves topical ocular delivery J. Pharm. Exp. 2019 370 814 822 10.1124/jpet.119.256446
157. Al Shuwaili A.H. Rasool B.K. Abdulrasool A.A. Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline Eur. J. Pharm. Biopharm. 2016 102 101 114 10.1016/j.ejpb.2016.02.013 26925505
158. Wu P.S. Li Y.S. Kuo Y.C. Tsai S.J. Lin C.C. Preparation and evaluation of novel transfersomes combined with the natural antioxidant resveratrol Molecules 2019 24 600 10.3390/molecules24030600
159. Pena-Rodríguez E. Moreno M.C. Blanco-Fernandez B. González J. Fernández-Campos F. Epidermal delivery of retinyl palmitate loaded transfersomes: Penetration and biodistribution studies Pharmaceutics 2020 12 112 10.3390/pharmaceutics12020112 32019144
160. Sundralingam U. Chakravarthi S. Radhakrishnan A.K. Muniyandy S. Palanisamy U.D. Efficacy of emu oil transfersomes for local transdermal delivery of 4-oh tamoxifen in the treatment of breast cancer Pharmaceutics 2020 12 807 10.3390/pharmaceutics12090807
161. Hasibi F. Nasirpour A. Varshosaz J. García-Manrique P. Blanco-López M.C. Gutiérrez G. Matos M. Formulation and characterization of taxifolin-loaded lipid nanovesicles (liposomes, niosomes, and transfersomes) for beverage fortification Eur. J. Lipid Sci. Technol. 2020 122 1900105 10.1002/ejlt.201900105
162. Caddeo C. Manca M.L. Peris J.E. Usach I. Diez-Sales O. Matos M. Fernàndez-Busquets X. Fadda A.M. Manconi M. Tocopherol-loaded transfersomes: In vitro antioxidant activity and efficacy in skin regeneration Int. J. Pharm. 2018 551 34 41 10.1016/j.ijpharm.2018.09.009 30201294
163. Pitta S.K. Dudhipala N. Narala A. Veerabrahma K. Development of zolmitriptan transfersomes by box-behnken design for nasal delivery: In vitro and in vivo evaluation Drug Dev. Ind. Pharm. 2018 44 484 492 10.1080/03639045.2017.1402918 29124986
164. Kateh Shamshiri M. Momtazi-Borojeni A.A. Khodabandeh Shahraky M. Rahimi F. Lecithin soybean phospholipid nano-transfersomes as potential carriers for transdermal delivery of the human growth hormone J. Cell Biochem. 2019 120 9023 9033 10.1002/jcb.28176 30506803
165. De Marco Almeida F. Silva C.N. de Araujo Lopes S.C. Santos D.M. Torres F.S. Cardoso F.L. Martinelli P.M. da Silva E.R. de Lima M.E. Miranda L.A.F. Physicochemical characterization and skin permeation of cationic transfersomes containing the synthetic peptide pnpp-19 Curr. Drug Deliv. 2018 15 1064 1071 10.2174/1567201815666180108170206 29318970
166. Semalty A. Semalty M. Rawat B.S. Singh D. Rawat M.S. Pharmacosomes: The lipid-based new drug delivery system Expert Opin. Drug Deliv. 2009 6 599 612 10.1517/17425240902967607 19519287
167. Patel J.L. Bharadia P.D. A review on: Pharmacosomes as a novel vesicular drug delivery system World J. Pharm. Res. 2012 1 456 469
168. Pathak K. Keshri L. Shah M. Lipid nanocarriers: Influence of lipids on product development and pharmacokinetics Crit. Rev. Drug Carr. Syst. 2011 28 357 393 10.1615/CritRevTherDrugCarrierSyst.v28.i4.20 21967401
169. Kapoor B. Gupta R. Singh S.K. Gulati M. Singh S. Prodrugs, phospholipids and vesicular delivery—An effective triumvirate of pharmacosomes Adv. Colloid Interface Sci. 2018 253 35 65 10.1016/j.cis.2018.01.003 29454464
170. K R Veena S.K.S. Pharmacosomes: A novel strategy for controlled drug delivery J. Pharm. Sci. Res. 2019 11 2590 2593
171. Al-kaf A.G.A. Othman A.M. A review on pharmacosomes: An emerging novel vesicular drug delivery system Univers. J. Pharm. Res. 2017 2 21-4
172. Semalty A. Semalty M. Rawat B.S. Singh D. Rawat M.S. Development and evaluation of pharmacosomes of aceclofenac Indian J. Pharm. Sci. 2010 72 576 581 10.4103/0250-474X.78523 21694988
173. Xue F. Lin X. Cai Z. Liu X. Ma Y. Wu M. Doxifluridine-based pharmacosomes delivering mir-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma Colloids Surf. B Biointerfaces 2021 197 111367 10.1016/j.colsurfb.2020.111367 33007506
174. Soman M.D. Dharan S.S. Mathew L.T. Formulation and evaluation of selective cox-2 inhibitor loaded pharmacosomes for the treatment of rheumatoid arthritis J. Pharm. Sci. Res. 2020 12 1502 1509
175. Jin S. Du Z. Guo H. Zhang H. Ren F. Wang P. Novel targeted anti-tumor nanoparticles developed from folic acid-modified 2-deoxyglucose Int. J. Mol. Sci. 2019 20 697 10.3390/ijms20030697 30736291
176. Amirinejad M. Davoodi J. Abbaspour M.R. Akhgari A. Hadizadeh F. Badiee A. Preparation, characterization and improved release profile of ibuprofen-phospholipid association J. Drug Deliv. Sci. Technol. 2020 60 101951 10.1016/j.jddst.2020.101951
177. Kotha Y. Kandhula A.G. Janapareddi K. Development and characterization of levodopa loaded pharmacosomes for brain targeting via intranasal route: Pharmacodynamic evaluation in rats J. Young Pharm. 2020 12 s56 s62 10.5530/jyp.2020.12s.47
178. Kusuma D.P.J.K. Sundaraseelan. Formulation and evaluation of pharmacosomal gel loaded with nsaid World J. Pharm. Med. Res. 2018 4 81 88
179. Pal T. Design, fabrication and evaluation of rosuvastatin pharmacosome—A novel sustained release drug delivery system Eur. J. Pharm. Med. Res. 2016 3 332 350
180. Gebicki J.M. Hicks M. Ufasomes are stable particles surrounded by unsaturated fatty acid membranes Nature 1973 243 232 234 10.1038/243232a0 4706295
181. Arundhasree R. Aiswarya R. Kumar A.R. Kumar S. Nair S. Ufasomes: Unsaturated fatty acid based vesicular drug delivery system Int. J. Appl. Pharm. 2021 13 76 83 10.22159/ijap.2021v13i2.39526
182. Morigaki K. Walde P. Fatty acid vesicles Curr. Opin. Colloid Interface Sci. 2007 12 75 80 10.1016/j.cocis.2007.05.005
183. Cristiano M.C. Froiio F. Mancuso A. Cosco D. Dini L. Di Marzio L. Fresta M. Paolino D. Oleuropein-laded ufasomes improve the nutraceutical efficacy Nanomaterials 2021 11 105 10.3390/nano11010105 33406805
184. Salama A.H. Aburahma M.H. Ufasomes nano-vesicles-based lyophilized platforms for intranasal delivery of cinnarizine: Preparation, optimization, ex-vivo histopathological safety assessment and mucosal confocal imaging Pharm. Dev. Technol 2016 21 706 715 10.3109/10837450.2015.1048553 25996631
185. Kumar P. Singh S.K. Handa V. Kathuria H. Oleic acid nanovesicles of minoxidil for enhanced follicular delivery Medicines 2018 5 103 10.3390/medicines5030103
186. Kaur N. Garg R. Devgan M. Singh A. Optimization and antifungal activity determination of tea tree oil containing oxiconazole loaded ufasomes gel against candida albicans Energy Environ. Focus 2016 5 287 294 10.1166/eef.2016.1230
187. Bhattacharya S. Preparation and characterizations of glyceryl oleate ufasomes of terbinafine hydrochloride: A novel approach to trigger candida albicans fungal infection Future J. Pharm. Sci. 2021 7 3 10.1186/s43094-020-00143-w
188. Ting Y. Jiang Y. Ho C.-T. Huang Q. Common delivery systems for enhancing in vivo bioavailability and biological efficacy of nutraceuticals J. Funct. Foods 2014 7 112 128 10.1016/j.jff.2013.12.010
189. Khan J. Alexander A. Ajazuddin Saraf S. Saraf S. Recent advances and future prospects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives J. Control. Release 2013 168 50 60 10.1016/j.jconrel.2013.02.025 23474031
190. Alharbi W.S. Almughem F.A. Almehmady A.M. Jarallah S.J. Alsharif W.K. Alzahrani N.M. Alshehri A.A. Phytosomes as an emerging nanotechnology platform for the topical delivery of bioactive phytochemicals Pharmaceutics 2021 13 1475 10.3390/pharmaceutics13091475 34575551
191. Sharma S. Sahu A.N. Development, characterization, and evaluation of hepatoprotective effect of abutilon indicum and piper longum phytosomes Pharmacogn. Res. 2016 8 29 36
192. Mancini S. Nardo L. Gregori M. Ribeiro I. Mantegazza F. Delerue-Matos C. Masserini M. Grosso C. Functionalized liposomes and phytosomes loading annona muricata l. Aqueous extract: Potential nanoshuttles for brain-delivery of phenolic compounds Phytomedicine 2018 42 233 244 10.1016/j.phymed.2018.03.053 29655691
193. Huang Z. Brennan C.S. Zhao H. Liu J. Guan W. Mohan M.S. Stipkovits L. Zheng H. Kulasiri D. Fabrication and assessment of milk phospholipid-complexed antioxidant phytosomes with vitamin c and e: A comparison with liposomes Food Chem. 2020 324 126837 10.1016/j.foodchem.2020.126837 32339791
194. Yu F. Li Y. Chen Q. He Y. Wang H. Yang L. Guo S. Meng Z. Cui J. Xue M. Monodisperse microparticles loaded with the self-assembled berberine-phospholipid complex-based phytosomes for improving oral bioavailability and enhancing hypoglycemic efficiency Eur. J. Pharm. Biopharm. 2016 103 136 148 10.1016/j.ejpb.2016.03.019 27020531
195. Molaveisi M. Shahidi Noghabi M. Parastouei K. Taheri R.A. Fate of nano-phytosomes containing bioactive compounds of echinacea extract in an acidic food beverage Food Struct. 2021 27 100177 10.1016/j.foostr.2021.100177
196. Kim S.M. Jung J.I. Chai C. Imm J.Y. Characteristics and glucose uptake promoting effect of chrysin-loaded phytosomes prepared with different phospholipid matrices Nutrients 2019 11 2549 10.3390/nu11102549 31652637
197. Kim S.M. Imm J.Y. The effect of chrysin-loaded phytosomes on insulin resistance and blood sugar control in type 2 diabetic db/db mice Molecules 2020 25 5503 10.3390/molecules25235503
198. Xu L. Xu D. Li Z. Gao Y. Chen H. Synthesis and potent cytotoxic activity of a novel diosgenin derivative and its phytosomes against lung cancer cells Beilstein J. Nanotechnol. 2019 10 1933 1942 10.3762/bjnano.10.189 31598460
199. Udapurkar P. Bhusnure D.O. Kamble S. Diosmin phytosomes: Development, optimization and physicochemical characterization Indian J. Pharm. Educ. Res. 2018 52 s29 s36 10.5530/ijper.52.4s.73
200. Islam N. Irfan M. Hussain T. Mushtaq M. Khan I.U. Yousaf A.M. Ghori M.U. Shahzad Y. Piperine phytosomes for bioavailability enhancement of domperidone J. Liposome Res. 2021 4 1 9 10.1080/08982104.2021.1918153
201. Karole S. Gautam G.K. Gupta S.K. Preparation and evaluation of phytosomes containing ethanolic extract of leaves of bombax ceiba for hepatoprotective activity Pharma Innov. 2019 8 22 26
202. Rathee S. Kamboj A. Optimization and development of antidiabetic phytosomes by the box-behnken design J. Liposome Res. 2018 28 161 172 10.1080/08982104.2017.1311913 28337938
203. Komeil I.A. El-Refaie W.M. Gowayed M.A. El-Ganainy S.O. El Achy S.N. Huttunen K.M. Abdallah O.Y. Oral genistein-loaded phytosomes with enhanced hepatic uptake, residence and improved therapeutic efficacy against hepatocellular carcinoma Int. J. Pharm. 2021 601 120564 10.1016/j.ijpharm.2021.120564 33812970
204. Alhakamy N.A. A Fahmy U. Badr-Eldin S.M. Ahmed O.A.A. Asfour H.Z. Aldawsari H.M. Algandaby M.M. Eid B.G. Abdel-Naim A.B. Awan Z.A. Optimized icariin phytosomes exhibit enhanced cytotoxicity and apoptosis-inducing activities in ovarian cancer cells Pharmaceutics 2020 12 346 10.3390/pharmaceutics12040346
205. Rhatih Eka S. Silvia S. Fadlina Chany S. Formulation and characterization of bitter melon extract (momordica charantia) loaded phytosomes Pharmacogn. J. 2019 11 1235 1241 10.5530/pj.2019.11.192
206. Direito R. Reis C. Roque L. Gonçalves M. Sanches-Silva A. Gaspar M.M. Pinto R. Rocha J. Sepodes B. Rosário Bronze M. Phytosomes with persimmon (diospyros kaki l.) extract: Preparation and preliminary demonstration of in vivo tolerability Pharmaceutics 2019 11 296 10.3390/pharmaceutics11060296
207. Permana A.D. Utami R.N. Courtenay A.J. Manggau M.A. Donnelly R.F. Rahman L. Phytosomal nanocarriers as platforms for improved delivery of natural antioxidant and photoprotective compounds in propolis: An approach for enhanced both dissolution behaviour in biorelevant media and skin retention profiles J. Photochem. Photobiol. B Biol. 2020 205 111846 10.1016/j.jphotobiol.2020.111846 32151785
208. Vu H.T.H. Hook S.M. Siqueira S.D. Müllertz A. Rades T. McDowell A. Are phytosomes a superior nanodelivery system for the antioxidant rutin? Int. J. Pharm. 2018 548 82 91 10.1016/j.ijpharm.2018.06.042 29933062
209. El-Batal A. Elmenshawi S. Ali A. Eldbaiky E. Preparation and characterization of silymarin nanocrystals and phytosomes with investigation of their stability using gamma irradiation Indian J. Pharm. Educ. Res. 2018 52 S174 S183 10.5530/ijper.52.4s.96
210. Kumar S. Baldi A. Sharma D.K. In vitro antioxidant assay guided ex vivo investigation of cytotoxic effect of phytosomes assimilating taxifolin rich fraction of cedrus deodara bark extract on human breast cancer cell lines (mcf7) J. Drug Deliv. Sci. Technol. 2021 63 102486 10.1016/j.jddst.2021.102486
211. Alhakamy N.A. Badr-Eldin S.M. Fahmy U.A. Alruwaili N.K. Awan Z.A. Caruso G. Alfaleh M.A. Alaofi A.L. Arif F.O. Ahmed O.A.A. Thymoquinone-loaded soy-phospholipid-based phytosomes exhibit anticancer potential against human lung cancer cells Pharmaceutics 2020 12 761 10.3390/pharmaceutics12080761
212. Freag M.S. Saleh W.M. Abdallah O.Y. Laminated chitosan-based composite sponges for transmucosal delivery of novel protamine-decorated tripterine phytosomes: Ex-vivo mucopenetration and in-vivo pharmacokinetic assessments Carbohydr. Polym. 2018 188 108 120 10.1016/j.carbpol.2018.01.095 29525146
213. Zhu S. Luo C. Feng W. Li Y. Zhu M. Sun S. Zhang X. Selenium-deposited tripterine phytosomes ameliorate the antiarthritic efficacy of the phytomedicine via a synergistic sensitization Int. J. Pharm. 2020 578 119104 10.1016/j.ijpharm.2020.119104 32018017
214. Ittadwar P. Puranik P. Novel umbelliferone phytosomes: Development and optimization using experimental design approach and evaluation of photo-protective and antioxidant activity Int. J. Pharm. Pharm. Sci. 2016 9 218 10.22159/ijpps.2017v9i1.14635
215. Xie X. He D. Wu Y. Wang T. Zhong C. Zhang J. Catanionic hybrid lipid nanovesicles for improved bioavailability and efficacy of chemotherapeutic drugs Bio-Carrier Vectors: Methods and Protocols Narayanan K. Springer US New York, NY, USA 2021 57 68
216. Safran S.A. Pincus P. Andelman D. Theory of spontaneous vesicle formation in surfactant mixtures Science 1990 248 354 356 10.1126/science.248.4953.354 17784490
217. Lozano N. Pérez L. Pons R. Pinazo A. Diacyl glycerol arginine-based surfactants: Biological and physicochemical properties of catanionic formulations Amino Acids 2011 40 721 729 10.1007/s00726-010-0710-4 20676901
218. Pinazo A. Pons R. Marqués A. Farfan M. da Silva A. Perez L. Biocompatible catanionic vesicles from arginine-based surfactants: A new strategy to tune the antimicrobial activity and cytotoxicity of vesicular systems Pharmaceutics 2020 12 857 10.3390/pharmaceutics12090857
219. Jain M. Marfatia A. Imam N. Ray D. Aswal V.K. Patel N.Y. Raval V.H. Kailasa S.K. Malek N.I. Ionic liquid-based catanionic vesicles: A de novo system to judiciously improve the solubility, stability and antimicrobial activity of curcumin J. Mol. Liq. 2021 341 117396 10.1016/j.molliq.2021.117396
220. Li S. Fang C. Zhang J. Liu B. Wei Z. Fan X. Sui Z. Tan Q. Catanionic lipid nanosystems improve pharmacokinetics and anti-lung cancer activity of curcumin Nanomedicine 2016 12 1567 1579 10.1016/j.nano.2016.02.007 26995093
221. Patel R. Ahmad Wani F. Mahfooz F. Mishra P. Abrar Siddiquee M. Interaction of human serum albumin with diclofenac incorporated in catanionic vesicles Mater. Today Proc. 2021 36 736 742 10.1016/j.matpr.2020.05.179
222. Gonçalves Lopes R.C.F. Silvestre O.F. Faria A.R. do Vale M.L.C. Marques E.F. Nieder J.B. Surface charge tunable catanionic vesicles based on serine-derived surfactants as efficient nanocarriers for the delivery of the anticancer drug doxorubicin Nanoscale 2019 11 5932 5941 10.1039/C8NR06346J 30556563
223. Geng S. Wang Y. Wang L. Kouyama T. Gotoh T. Wada S. Wang J.-Y. A light-responsive self-assembly formed by a cationic azobenzene derivative and sds as a drug delivery system Sci. Rep. 2017 7 39202 10.1038/srep39202 28051069
224. Richard K. Mann B.J. Qin A. Barry E.M. Ernst R.K. Vogel S.N. Monophosphoryl lipid a enhances efficacy of a francisella tularensis lvs-catanionic nanoparticle subunit vaccine against f. Tularensis schu s4 challenge by augmenting both humoral and cellular immunity Clin. Vaccine Immunol. 2017 24 e00574-16 10.1128/CVI.00574-16 28077440
225. Stagnoli S. Sosa Alderete L. Luna M.A. Agostini E. Falcone R.D. Niebylski A.M. Correa N.M. Catanionic nanocarriers as a potential vehicle for insulin delivery Colloids Surf. B Biointerfaces 2020 188 110759 10.1016/j.colsurfb.2019.110759 31887645
226. Seidel Z.P. Zhang X. MacMullan M.A. Graham N.A. Wang P. Lee C.T. Photo-triggered delivery of sirna and paclitaxel into breast cancer cells using catanionic vesicles ACS Appl. Bio Mater. 2020 3 7388 7398 10.1021/acsabm.0c00503
227. Kaur G. Berwal K. Sharma B. Chaudhary G.R. Gawali S.L. Hassan P.A. Enhanced antimicrobial photodynamic activity of photosensitizer encapsulated copper based metallocatanionic vesicles against e.Coli using visible light J. Mol. Liq. 2021 324 114688 10.1016/j.molliq.2020.114688
228. Sharma B. Thakur V. Kaur G. Chaudhary G.R. Efficient photodynamic therapy against gram-positive and gram-negative bacteria using rose bengal encapsulated in metallocatanionic vesicles in the presence of visible light ACS Appl. Bio Mater. 2020 3 8515 8524 10.1021/acsabm.0c00901
229. Russo Krauss I. Imperatore R. De Santis A. Luchini A. Paduano L. D’Errico G. Structure and dynamics of cetyltrimethylammonium chloride-sodium dodecylsulfate (ctac-sds) catanionic vesicles: High-value nano-vehicles from low-cost surfactants J. Colloid Interface Sci. 2017 501 112 122 10.1016/j.jcis.2017.04.032 28437699
230. Torres-Luna C. Koolivand A. Fan X. Agrawal N.R. Hu N. Zhu Y. Domszy R. Briber R.M. Wang N.S. Yang A. Formation of drug-participating catanionic aggregates for extended delivery of non-steroidal anti-inflammatory drugs from contact lenses Biomolecules 2019 9 593 10.3390/biom9100593
231. Jiang Y. Hu X. Zhang J. Jin G. Luan Y. Chlorambucil prodrug-participating catanionic aggregates for sustained drug release and improved antitumour activity J. Mol. Liq. 2018 274 556 561 10.1016/j.molliq.2018.10.165
232. Zhang M. Zhao S.X. Ding B. Zhang Y.Q. Sodium n-lauryl amino acids derived from silk protein can form catanionic aggregates with cytarabine as novel anti-tumor drug delivery systems Drug Deliv. 2020 27 482 490 10.1080/10717544.2020.1742250 32212952
233. Stein D.C. H. Stocker L. Powell A.E. Kebede S. Watts D. Williams E. Soto N. Dhabaria A. Fenselau C. Ganapati S. Extraction of membrane components from neisseria gonorrhoeae using catanionic surfactant vesicles: A new approach for the study of bacterial surface molecules Pharmaceutics 2020 12 787 10.3390/pharmaceutics12090787
234. Srivastava D. Liu C. Lv J. Deb D. Qiao W. Enhanced intercellular release of anticancer drug by using nano-sized catanionic vesicles of doxorubicin hydrochloride and gemini surfactants J. Mol. Liq. 2018 259 398 410 10.1016/j.molliq.2018.03.065
235. Alp G. Aydogan N. Enhancing the spreading behavior on pulmonary mucus mimicking subphase via catanionic surfactant solutions: Toward effective drug delivery through the lungs Mol. Pharm. 2018 15 1361 1370 10.1021/acs.molpharmaceut.8b00086 29436839
236. Rajput S.M. Kumar S. Aswal V.K. El Seoud O.A. Malek N.I. Kailasa S.K. Drug-induced micelle-to-vesicle transition of a cationic gemini surfactant: Potential applications in drug delivery Chemphyschem 2018 19 865 872 10.1002/cphc.201701134 29319220
237. Garcia M.T. Ribosa I. Gonzalez J.J. Comelles F. Catanionic mixtures of surface-active ionic liquids and n-lauroyl sarcosinate: Surface adsorption, aggregation behavior and microbial toxicity J. Mol. Liq. 2020 318 114040 10.1016/j.molliq.2020.114040
238. Garcia M.T. Ribosa I. González J. Comelles F. Surface activity, self-aggregation and antimicrobial activity of catanionic mixtures of surface active imidazolium- or pyridinium-based ionic liquids and sodium bis(2-ethylhexyl) sulfosuccionate J. Mol. Liq. 2020 303 112637 10.1016/j.molliq.2020.112637
239. Ruiz A. Pinazo A. Pérez L. Manresa A. Marqués A.M. Green catanionic gemini surfactant–lichenysin mixture: Improved surface, antimicrobial, and physiological properties ACS Appl. Mater. Interfaces 2017 9 22121 22131 10.1021/acsami.7b03348 28636319
240. Pérez L. Pinazo A. Morán M.C. Pons R. Aggregation behavior, antibacterial activity and biocompatibility of catanionic assemblies based on amino acid-derived surfactants Int. J. Mol. Sci. 2020 21 8912 10.3390/ijms21238912
241. Roig F. Blanzat M. Solans C. Esquena J. García-Celma M.J. Hyaluronan based materials with catanionic sugar-derived surfactants as drug delivery systems Colloids Surf. B Biointerfaces 2018 164 218 223 10.1016/j.colsurfb.2018.01.037 29413599
242. Simeone P. Bologna G. Lanuti P. Pierdomenico L. Guagnano M.T. Pieragostino D. Del Boccio P. Vergara D. Marchisio M. Miscia S. Extracellular vesicles as signaling mediators and disease biomarkers across biological barriers Int. J. Mol. Sci. 2020 21 2514 10.3390/ijms21072514
243. Rimmer M.P. Gregory C.D. Mitchell R.T. Extracellular vesicles in urological malignancies Biochim. Biophys. Acta Rev. Cancer 2021 1876 188570 10.1016/j.bbcan.2021.188570 34019971
244. O’Brien K. Breyne K. Ughetto S. Laurent L.C. Breakefield X.O. Rna delivery by extracellular vesicles in mammalian cells and its applications Nat. Rev. Mol. Cell Biol. 2020 21 585 606 10.1038/s41580-020-0251-y 32457507
245. O’Brien K.P. Khan S. Gilligan K.E. Zafar H. Lalor P. Glynn C. O’Flatharta C. Ingoldsby H. Dockery P. De Bhulbh A. Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (ev)-encapsulated microrna-379 Oncogene 2018 37 2137 2149 10.1038/s41388-017-0116-9 29367765
246. Limongi T. Susa F. Dumontel B. Racca L. Perrone Donnorso M. Debellis D. Cauda V. Extracellular vesicles tropism: A comparative study between passive innate tropism and the active engineered targeting capability of lymphocyte-derived evs Membranes 2021 11 886 10.3390/membranes11110886 34832115
247. Susa F. Limongi T. Dumontel B. Vighetto V. Cauda V. Engineered extracellular vesicles as a reliable tool in cancer nanomedicine Cancers 2019 11 1979 10.3390/cancers11121979
248. Coleman L.G. The emerging world of subcellular biological medicine: Extracellular vesicles as novel biomarkers, targets, and therapeutics Neural. Regen. Res. 2022 17 1020 1022 10.4103/1673-5374.324846 34558528
249. Ikeda G. Santoso M.R. Tada Y. Li A.M. Vaskova E. Jung J.-H. O’Brien C. Egan E. Ye J. Yang P.C. Mitochondria-rich extracellular vesicles from autologous stem cell–derived cardiomyocytes restore energetics of ischemic myocardium J. Am. Coll. Cardiol. 2021 77 1073 1088 10.1016/j.jacc.2020.12.060 33632482
250. de Jong O.G. Kooijmans S.A.A. Murphy D.E. Jiang L. Evers M.J.W. Sluijter J.P.G. Vader P. Schiffelers R.M. Drug delivery with extracellular vesicles: From imagination to innovation Acc. Chem. Res. 2019 52 1761 1770 10.1021/acs.accounts.9b00109 31181910
251. Elsharkasy O.M. Nordin J.Z. Hagey D.W. de Jong O.G. Schiffelers R.M. Andaloussi S.E.L. Vader P. Extracellular vesicles as drug delivery systems: Why and how? Adv. Drug Deliv. Rev. 2020 159 332 343 10.1016/j.addr.2020.04.004 32305351
252. Herrmann I.K. Wood M.J.A. Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform Nat. Nanotechnol. 2021 16 748 759 10.1038/s41565-021-00931-2 34211166
253. Rao L. Xia S. Xu W. Tian R. Yu G. Gu C. Pan P. Meng Q.F. Cai X. Qu D. Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines Proc. Natl Acad Sci USA 2020 117 27141 27147 10.1073/pnas.2014352117 33024017
254. Munagala R. Aqil F. Jeyabalan J. Agrawal A.K. Mudd A.M. Kyakulaga A.H. Singh I.P. Vadhanam M.V. Gupta R.C. Exosomal formulation of anthocyanidins against multiple cancer types Cancer Lett. 2017 393 94 102 10.1016/j.canlet.2017.02.004 28202351
255. Tran P.H.L. Wang T. Yin W. Tran T.T.D. Nguyen T.N.G. Lee B.-J. Duan W. Aspirin-loaded nanoexosomes as cancer therapeutics Int. J. Pharm. 2019 572 118786 10.1016/j.ijpharm.2019.118786 31669214
256. Zhuang M. Du D. Pu L. Song H. Deng M. Long Q. Yin X. Wang Y. Rao L. Spion-decorated exosome delivered bay55-9837 targeting the pancreas through magnetism to improve the blood glc response Small 2019 15 1903135 10.1002/smll.201903135
257. Gao Z.S. Zhang C.J. Xia N. Tian H. Li D.Y. Lin J.Q. Mei X.F. Wu C. Berberine-loaded m2 macrophage-derived exosomes for spinal cord injury therapy Acta Biomater. 2021 126 211 223 10.1016/j.actbio.2021.03.018 33722788
258. Patel N. Kommineni N. Surapaneni S.K. Kalvala A. Yaun X. Gebeyehu A. Arthur P. Duke L.C. York S.B. Bagde A. Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models Int. J. Pharm. 2021 607 120943 10.1016/j.ijpharm.2021.120943 34324983
259. Zhang X. Liu L. Tang M. Li H. Guo X. Yang X. The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells Drug Dev. Ind. Pharm. 2020 46 1150 1162 10.1080/03639045.2020.1776320 32482115
260. He R. Jiang Y. Shi Y. Liang J. Zhao L. Curcumin-laden exosomes target ischemic brain tissue and alleviate cerebral ischemia-reperfusion injury by inhibiting ros-mediated mitochondrial apoptosis Mater. Sci. Eng. C 2020 117 111314 10.1016/j.msec.2020.111314
261. Wang H. Sui H. Zheng Y. Jiang Y. Shi Y. Liang J. Zhao L. Curcumin-primed exosomes potently ameliorate cognitive function in ad mice by inhibiting hyperphosphorylation of the tau protein through the akt/gsk-3β pathway Nanoscale 2019 11 7481 7496 10.1039/C9NR01255A 30942233
262. Qiu B. Xu X. Yi P. Hao Y. Curcumin reinforces msc-derived exosomes in attenuating osteoarthritis via modulating the mir-124/nf-kb and mir-143/rock1/tlr9 signalling pathways J. Cell Mol. Med. 2020 24 10855 10865 10.1111/jcmm.15714 32776418
263. Kang J.Y. Kim H.E. Mun D.S. Yun N.R. Joung B.Y. Curcumin-loaded extracellular vesicles endowed with heart targeting properties facilitate treatment of myocardial infarction Eur. Heart J. 2020 41 3609 10.1093/ehjci/ehaa946.3609
264. Tian T. Zhang H.-X. He C.-P. Fan S. Zhu Y.-L. Qi C. Huang N.-P. Xiao Z.-D. Lu Z.-H. Tannous B.A. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy Biomaterials 2018 150 137 149 10.1016/j.biomaterials.2017.10.012 29040874
265. Kim G. Lee Y. Ha J. Han S. Lee M. Engineering exosomes for pulmonary delivery of peptides and drugs to inflammatory lung cells by inhalation J. Control. Release 2021 330 684 695 10.1016/j.jconrel.2020.12.053 33388343
266. Pérez-González R. Sahoo S. Gauthier S.A. Kim Y. Li M. Kumar A. Pawlik M. Benussi L. Ghidoni R. Levy E. Neuroprotection mediated by cystatin c-loaded extracellular vesicles Sci. Rep. 2019 9 11104 10.1038/s41598-019-47524-7 31367000
267. Wang Y. Guo M. Lin D. Liang D. Zhao L. Zhao R. Wang Y. Docetaxel-loaded exosomes for targeting non-small cell lung cancer: Preparation and evaluation in vitro and in vivo Drug Deliv. 2021 28 1510 1523 10.1080/10717544.2021.1951894 34263685
268. Cenik M. Abas B.I. Kocabiyik B. Demirbolat G.M. Cevik O. Development of a new drug delivery system from hela-derived exosomes and the effect of docetaxel-loaded exosomes on mitochondrial apoptosis J. Pharm. Innov. 2021 1 9 10.1007/s12247-021-09566-1
269. Qu M. Lin Q. Huang L. Fu Y. Wang L. He S. Fu Y. Yang S. Zhang Z. Zhang L. Dopamine-loaded blood exosomes targeted to brain for better treatment of parkinson’s disease J. Control. Release 2018 287 156 166 10.1016/j.jconrel.2018.08.035 30165139
270. Guo L. Zhang Y. Wei R. Zhang X. Wang C. Feng M. Proinflammatory macrophage-derived microvesicles exhibit tumor tropism dependent on ccl2/ccr2 signaling axis and promote drug delivery via snare-mediated membrane fusion Theranostics 2020 10 6581 6598 10.7150/thno.45528 32550891
271. Bagheri E. Abnous K. Farzad S.A. Taghdisi S.M. Ramezani M. Alibolandi M. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer Life Sci. 2020 261 118369 10.1016/j.lfs.2020.118369 32882265
272. Thakur A. Sidu R.K. Zou H. Alam M.K. Yang M. Lee Y. Inhibition of glioma cells’ proliferation by doxorubicin-loaded exosomes via microfluidics Int. J. Nanomed. 2020 15 8331 8343 10.2147/IJN.S263956
273. Li D. Yao S. Zhou Z. Shi J. Huang Z. Wu Z. Hyaluronan decoration of milk exosomes directs tumor-specific delivery of doxorubicin Carbohydr. Res. 2020 493 108032 10.1016/j.carres.2020.108032 32417443
274. Schindler C. Collinson A. Matthews C. Pointon A. Jenkinson L. Minter R.R. Vaughan T.J. Tigue N.J. Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency PLoS ONE 2019 14 e0214545 10.1371/journal.pone.0214545 30925190
275. Wei H. Chen J. Wang S. Fu F. Zhu X. Wu C. Liu Z. Zhong G. Lin J. A nanodrug consisting of doxorubicin and exosome derived from mesenchymal stem cells for osteosarcoma treatment in vitro Int. J. Nanomed. 2019 14 8603 8610 10.2147/IJN.S218988 31802872
276. Li Y. Gao Y. Gong C. Wang Z. Xia Q. Gu F. Hu C. Zhang L. Guo H. Gao S. A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer Nanomedicine 2018 14 1973 1985 10.1016/j.nano.2018.05.020 29935333
277. Hadla M. Palazzolo S. Corona G. Caligiuri I. Canzonieri V. Toffoli G. Rizzolio F. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models Nanomedicine 2016 11 2431 2441 10.2217/nnm-2016-0154 27558906
278. Li F. Zhao L. Shi Y. Liang J. Edaravone-loaded macrophage-derived exosomes enhance neuroprotection in the rat permanent middle cerebral artery occlusion model of stroke Mol. Pharm. 2020 17 3192 3201 10.1021/acs.molpharmaceut.0c00245 32786956
279. Yu M. Gai C. Li Z. Ding D. Zheng J. Zhang W. Lv S. Li W. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells Cancer Sci. 2019 110 3173 3182 10.1111/cas.14181 31464035
280. Li Y.J. Wu J.Y. Wang J.M. Hu X.B. Cai J.X. Xiang D.X. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer Acta Biomater. 2020 101 519 530 10.1016/j.actbio.2019.10.022 31629893
281. Lin Q. Qu M. Zhou B. Patra H.K. Sun Z. Luo Q. Yang W. Wu Y. Zhang Y. Li L. Exosome-like nanoplatform modified with targeting ligand improves anti-cancer and anti-inflammation effects of imperialine J. Control. Release 2019 311–312 104 116 10.1016/j.jconrel.2019.08.037
282. Millard M. Posty S. Piffoux M. Jasniewski J. Lassalle H.-P. Yakavets I. Gazeau F. Wilhelm C. Silva A.K.A. Bezdetnaya L. Mthpc-loaded extracellular vesicles significantly improve mthpc diffusion and photodynamic activity in preclinical models Pharmaceutics 2020 12 676 10.3390/pharmaceutics12070676
283. Millard M. Yakavets I. Piffoux M. Brun A. Gazeau F. Guigner J.-M. Jasniewski J. Lassalle H.-P. Wilhelm C. Bezdetnaya L. Mthpc-loaded extracellular vesicles outperform liposomal and free mthpc formulations by an increased stability, drug delivery efficiency and cytotoxic effect in tridimensional model of tumors Drug Deliv. 2018 25 1790 1801 10.1080/10717544.2018.1513609 30785308
284. Ye Z. Zhang T. He W. Jin H. Liu C. Yang Z. Ren J. Methotrexate-loaded extracellular vesicles functionalized with therapeutic and targeted peptides for the treatment of glioblastoma multiforme ACS Appl. Mater. Interfaces 2018 10 12341 12350 10.1021/acsami.7b18135 29564886
285. Zhu Q. Ling X. Yang Y. Zhang J. Li Q. Niu X. Hu G. Chen B. Li H. Wang Y. Embryonic stem cells-derived exosomes endowed with targeting properties as chemotherapeutics delivery vehicles for glioblastoma therapy Adv. Sci. 2019 6 1801899 10.1002/advs.201801899 30937268
286. Melzer C. Rehn V. Yang Y. Bähre H. von der Ohe J. Hass R. Taxol-loaded msc-derived exosomes provide a therapeutic vehicle to target metastatic breast cancer and other carcinoma cells Cancers 2019 11 798 10.3390/cancers11060798 31181850
287. Coccè V. Franzè S. Brini A.T. Giannì A.B. Pascucci L. Ciusani E. Alessandri G. Farronato G. Cavicchini L. Sordi V. In vitro anticancer activity of extracellular vesicles (evs) secreted by gingival mesenchymal stromal cells primed with paclitaxel Pharmaceutics 2019 11 61 10.3390/pharmaceutics11020061
288. Brini A.T. Coccè V. Ferreira L.M.J. Giannasi C. Cossellu G. Giannì A.B. Angiero F. Bonomi A. Pascucci L. Falchetti M.L. Cell-mediated drug delivery by gingival interdental papilla mesenchymal stromal cells (ginpa-mscs) loaded with paclitaxel Expert Opin. Drug Deliv. 2016 13 789 798 10.1517/17425247.2016.1167037 26986001
289. Kim M.S. Haney M.J. Zhao Y. Yuan D. Deygen I. Klyachko N.L. Kabanov A.V. Batrakova E.V. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: In vitro and in vivo evaluations Nanomedicine 2018 14 195 204 10.1016/j.nano.2017.09.011 28982587
290. Agrawal A.K. Aqil F. Jeyabalan J. Spencer W.A. Beck J. Gachuki B.W. Alhakeem S.S. Oben K. Munagala R. Bondada S. Milk-derived exosomes for oral delivery of paclitaxel Nanomedicine 2017 13 1627 1636 10.1016/j.nano.2017.03.001 28300659
291. Petrella F. Coccè V. Masia C. Milani M. Salè E.O. Alessandri G. Parati E. Sisto F. Pentimalli F. Brini A.T. Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells Biomed. Pharm. 2017 87 755 758 10.1016/j.biopha.2017.01.118 28153512
292. Kim M.S. Haney M.J. Zhao Y. Mahajan V. Deygen I. Klyachko N.L. Inskoe E. Piroyan A. Sokolsky M. Okolie O. Development of exosome-encapsulated paclitaxel to overcome mdr in cancer cells Nanomed. Nanotechnol. Biol. Med. 2016 12 655 664 10.1016/j.nano.2015.10.012
293. Garofalo M. Villa A. Rizzi N. Kuryk L. Rinner B. Cerullo V. Yliperttula M. Mazzaferro V. Ciana P. Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice J. Control. Release 2019 294 165 175 10.1016/j.jconrel.2018.12.022 30557650
294. Gao J. Wang S. Wang Z. High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (evs) for anti-inflammation therapy Biomaterials 2017 135 62 73 10.1016/j.biomaterials.2017.05.003 28494264
295. Qi Y. Guo L. Jiang Y. Shi Y. Sui H. Zhao L. Brain delivery of quercetin-loaded exosomes improved cognitive function in ad mice by inhibiting phosphorylated tau-mediated neurofibrillary tangles Drug Deliv. 2020 27 745 755 10.1080/10717544.2020.1762262 32397764
296. Liu H. Shen M. Zhao D. Ru D. Duan Y. Ding C. Li H. The effect of triptolide-loaded exosomes on the proliferation and apoptosis of human ovarian cancer skov3 cells Biomed. Res. Int. 2019 2019 2595801 10.1155/2019/2595801 31240207
297. Yang X. Xie B. Peng H. Shi G. Sreenivas B. Guo J. Wang C. He Y. Eradicating intracellular mrsa via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes J. Control. Release 2021 329 454 467 10.1016/j.jconrel.2020.11.045 33253805
298. Thomas B.L. Eldridge S.E. Nosrati B. Alvarez M. Thorup A.-S. Nalesso G. Caxaria S. Barawi A. Nicholson J.G. Perretti M. Wnt3a-loaded exosomes enable cartilage repair J. Extracell. Vesicles 2021 10 e12088 10.1002/jev2.12088 34025953
299. Barjesteh T. Mansur S. Bao Y. Inorganic nanoparticle-loaded exosomes for biomedical applications Molecules 2021 26 1135 10.3390/molecules26041135 33672706
300. Yong T. Zhang X. Bie N. Zhang H. Zhang X. Li F. Hakeem A. Hu J. Gan L. Santos H.A. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy Nat. Commun. 2019 10 3838 10.1038/s41467-019-11718-4 31444335
301. Niu W. Xiao Q. Wang X. Zhu J. Li J. Liang X. Peng Y. Wu C. Lu R. Pan Y. A biomimetic drug delivery system by integrating grapefruit extracellular vesicles and doxorubicin-loaded heparin-based nanoparticles for glioma therapy Nano Lett. 2021 21 1484 1492 10.1021/acs.nanolett.0c04753 33475372
302. Sancho-Albero M. Encabo-Berzosa M.d.M. Beltrán-Visiedo M. Fernández-Messina L. Sebastián V. Sánchez-Madrid F. Arruebo M. Santamaría J. Martín-Duque P. Efficient encapsulation of theranostic nanoparticles in cell-derived exosomes: Leveraging the exosomal biogenesis pathway to obtain hollow gold nanoparticle-hybrids Nanoscale 2019 11 18825 18836 10.1039/C9NR06183E 31595912
303. Khongkow M. Yata T. Boonrungsiman S. Ruktanonchai U.R. Graham D. Namdee K. Surface modification of gold nanoparticles with neuron-targeted exosome for enhanced blood–brain barrier penetration Sci. Rep. 2019 9 8278 10.1038/s41598-019-44569-6 31164665
304. Perets N. Betzer O. Shapira R. Brenstein S. Angel A. Sadan T. Ashery U. Popovtzer R. Offen D. Golden exosomes selectively target brain pathologies in neurodegenerative and neurodevelopmental disorders Nano Lett. 2019 19 3422 3431 10.1021/acs.nanolett.8b04148 30761901
305. Betzer O. Perets N. Angel A. Motiei M. Sadan T. Yadid G. Offen D. Popovtzer R. In vivo neuroimaging of exosomes using gold nanoparticles ACS Nano 2017 11 10883 10893 10.1021/acsnano.7b04495 28960957
306. Jc Bose R. Uday Kumar S. Zeng Y. Afjei R. Robinson E. Lau K. Bermudez A. Habte F. Pitteri S.J. Sinclair R. Tumor cell-derived extracellular vesicle-coated nanocarriers: An efficient theranostic platform for the cancer-specific delivery of anti-mir-21 and imaging agents ACS Nano 2018 12 10817 10832 10.1021/acsnano.8b02587 30346694
307. Lee J.R. Park B.W. Kim J. Choo Y.W. Kim H.Y. Yoon J.K. Kim H. Hwang J.W. Kang M. Kwon S.P. Nanovesicles derived from iron oxide nanoparticles-incorporated mesenchymal stem cells for cardiac repair Sci. Adv. 2020 6 eaaz0952 10.1126/sciadv.aaz0952 32494669
308. Li X. Wang Y. Shi L. Li B. Li J. Wei Z. Lv H. Wu L. Zhang H. Yang B. Magnetic targeting enhances the cutaneous wound healing effects of human mesenchymal stem cell-derived iron oxide exosomes J. Nanobiotechnol. 2020 18 113 10.1186/s12951-020-00670-x
309. Mulens-Arias V. Nicolás-Boluda A. Silva A.K.A. Gazeau F. Theranostic iron oxide nanoparticle cargo defines extracellular vesicle-dependent modulation of macrophage activation and migratory behavior Adv. Biosyst. 2018 2 1800079 10.1002/adbi.201800079
310. Altanerova U. Babincova M. Babinec P. Benejova K. Jakubechova J. Altanerova V. Zduriencikova M. Repiska V. Altaner C. Human mesenchymal stem cell-derived iron oxide exosomes allow targeted ablation of tumor cells via magnetic hyperthermia Int. J. Nanomed. 2017 12 7923 7936 10.2147/IJN.S145096
311. Piffoux M. Silva A.K.A. Lugagne J.-B. Hersen P. Wilhelm C. Gazeau F. Extracellular vesicle production loaded with nanoparticles and drugs in a trade-off between loading, yield and purity: Towards a personalized drug delivery system Adv. Biosyst. 2017 1 1700044 10.1002/adbi.201700044 32646153
312. Xiong F. Ling X. Chen X. Chen J. Tan J. Cao W. Ge L. Ma M. Wu J. Pursuing specific chemotherapy of orthotopic breast cancer with lung metastasis from docking nanoparticles driven by bioinspired exosomes Nano Lett. 2019 19 3256 3266 10.1021/acs.nanolett.9b00824 30965009
313. Lv W. Han Z. Li Y. Huang Y. Sun J. Lu X. Liu C. Exosome-coated zeolitic imidazolate framework nanoparticles for intracellular detection of ATP† Chin. J. Chem. 2021 39 2107 2112 10.1002/cjoc.202100162
314. Cheng G. Li W. Ha L. Han X. Hao S. Wan Y. Wang Z. Dong F. Zou X. Mao Y. Self-assembly of extracellular vesicle-like metal-organic framework nanoparticles for protection and intracellular delivery of biofunctional proteins J. Am. Chem. Soc. 2018 140 7282 7291 10.1021/jacs.8b03584 29809001
315. Illes B. Hirschle P. Barnert S. Cauda V. Wuttke S. Engelke H. Exosome-coated metal–organic framework nanoparticles: An efficient drug delivery platform Chem. Mater. 2017 29 8042 8046 10.1021/acs.chemmater.7b02358
316. Sancho-Albero M. Rubio-Ruiz B. Pérez-López A.M. Sebastián V. Martín-Duque P. Arruebo M. Santamaría J. Unciti-Broceta A. Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis Nat. Catal. 2019 2 864 872 10.1038/s41929-019-0333-4 31620674
317. Han Z. Lv W. Li Y. Chang J. Zhang W. Liu C. Sun J. Improving tumor targeting of exosomal membrane-coated polymeric nanoparticles by conjugation with aptamers ACS Appl. Bio Mater. 2020 3 2666 2673 10.1021/acsabm.0c00181
318. Liu C. Zhang W. Li Y. Chang J. Tian F. Zhao F. Ma Y. Sun J. Microfluidic sonication to assemble exosome membrane-coated nanoparticles for immune evasion-mediated targeting Nano Lett. 2019 19 7836 7844 10.1021/acs.nanolett.9b02841 31597431
319. Gao F. Xu L. Yang B. Fan F. Yang L. Kill the real with the fake: Eliminate intracellular staphylococcus aureus using nanoparticle coated with its extracellular vesicle membrane as active-targeting drug carrier ACS Infect. Dis 2019 5 218 227 10.1021/acsinfecdis.8b00212 30489062
320. Cao Y. Wu T. Zhang K. Meng X. Dai W. Wang D. Dong H. Zhang X. Engineered exosome-mediated near-infrared-ii region v(2)c quantum dot delivery for nucleus-target low-temperature photothermal therapy ACS Nano 2019 13 1499 1510 10.1021/acsnano.8b07224 30677286
321. Tayyaba Rehman F.U. Shaikh S. Tanziela Semcheddine F. Du T. Jiang H. Wang X. In situ self-assembled ag–fe3o4 nanoclusters in exosomes for cancer diagnosis J. Mater. Chem. B 2020 8 2845 2855 10.1039/C9TB02610J 32175535
322. Jia G. Han Y. An Y. Ding Y. He C. Wang X. Tang Q. Nrp-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo Biomaterials 2018 178 302 316 10.1016/j.biomaterials.2018.06.029 29982104
323. Qi H. Liu C. Long L. Ren Y. Zhang S. Chang X. Qian X. Jia H. Zhao J. Sun J. Blood exosomes endowed with magnetic and targeting properties for cancer therapy ACS Nano 2016 10 3323 3333 10.1021/acsnano.5b06939 26938862
324. Dumontel B. Susa F. Limongi T. Canta M. Racca L. Chiodoni A. Garino N. Chiabotto G. Centomo M.L. Pignochino Y. Zno nanocrystals shuttled by extracellular vesicles as effective trojan nano-horses against cancer cells Nanomedicine 2019 14 2815 2833 10.2217/nnm-2019-0231 31747855
325. Hill A.F. Extracellular vesicles and neurodegenerative diseases J. Neurosci. 2019 39 9269 9273 10.1523/JNEUROSCI.0147-18.2019 31748282
326. Yuan Q. Li X.-D. Zhang S.-M. Wang H.-W. Wang Y.-L. Extracellular vesicles in neurodegenerative diseases: Insights and new perspectives Genes Dis. 2021 8 124 132 10.1016/j.gendis.2019.12.001 33997159
327. Umwali Y. Yue C.B. Gabriel A.N.A. Zhang Y. Zhang X. Roles of exosomes in diagnosis and treatment of colorectal cancer World J. Clin. Cases 2021 9 4467 4479 10.12998/wjcc.v9.i18.4467 34222415
328. Zheng X. Hermann D.M. Bähr M. Doeppner T.R. The role of small extracellular vesicles in cerebral and myocardial ischemia—molecular signals, treatment targets, and future clinical translation Stem Cells 2021 39 403 413 10.1002/stem.3329 33432732
329. Jin Q. Wu P. Zhou X. Qian H. Xu W. Extracellular vesicles: Novel roles in neurological disorders Stem Cells Int. 2021 2021 6640836 10.1155/2021/6640836 33679989
330. Bruno S. Chiabotto G. Camussi G. Extracellular vesicles: A therapeutic option for liver fibrosis Int. J. Mol. Sci. 2020 21 4255 10.3390/ijms21124255 32549355
331. Ruan S. Greenberg Z. Pan X. Zhuang P. Erwin N. He M. Extracellular vesicles as an advanced delivery biomaterial for precision cancer immunotherapy Adv. Healthc. Mater. 2021 2100650 10.1002/adhm.202100650
332. Massaro C. Sgueglia G. Frattolillo V. Baglio S.R. Altucci L. Dell’Aversana C. Extracellular vesicle-based nucleic acid delivery: Current advances and future perspectives in cancer therapeutic strategies Pharmaceutics 2020 12 980 10.3390/pharmaceutics12100980
333. Haraszti R.A. Miller R. Didiot M.C. Biscans A. Alterman J.F. Hassler M.R. Roux L. Echeverria D. Sapp E. DiFiglia M. Optimized cholesterol-sirna chemistry improves productive loading onto extracellular vesicles Mol. Ther. 2018 26 1973 1982 10.1016/j.ymthe.2018.05.024 29937418
334. O’Loughlin A.J. Mäger I. de Jong O.G. Varela M.A. Schiffelers R.M. El Andaloussi S. Wood M.J.A. Vader P. Functional delivery of lipid-conjugated sirna by extracellular vesicles Mol. Ther. 2017 25 1580 1587 10.1016/j.ymthe.2017.03.021 28392161
335. Kanada M. Kim B.D. Hardy J.W. Ronald J.A. Bachmann M.H. Bernard M.P. Perez G.I. Zarea A.A. Ge T.J. Withrow A. Microvesicle-mediated delivery of minicircle DNA results in effective gene-directed enzyme prodrug cancer therapy Mol. Cancer Ther. 2019 18 2331 2342 10.1158/1535-7163.MCT-19-0299 31451563
336. Ito T. Sugiura K. Hasegawa A. Ouchi W. Yoshimoto T. Mizoguchi I. Inaba T. Hamada K. Eriguchi M. Koyama Y. Microbial antigen-presenting extracellular vesicles derived from genetically modified tumor cells promote antitumor activity of dendritic cells Pharmaceutics 2021 13 57 10.3390/pharmaceutics13010057 33406722
337. Dave K.M. Zhao W. Hoover C. D’Souza A. Manickam D.S. Extracellular vesicles derived from a human brain endothelial cell line increase cellular atp levels AAPS PharmSciTech 2021 22 18 10.1208/s12249-020-01892-w 33389284
338. Haney M.J. Klyachko N.L. Harrison E.B. Zhao Y. Kabanov A.V. Batrakova E.V. Tpp1 delivery to lysosomes with extracellular vesicles and their enhanced brain distribution in the animal model of batten disease Adv. Healthc. Mater. 2019 8 1801271 10.1002/adhm.201801271
339. Usman W.M. Pham T.C. Kwok Y.Y. Vu L.T. Ma V. Peng B. Chan Y.S. Wei L. Chin S.M. Azad A. Efficient rna drug delivery using red blood cell extracellular vesicles Nat. Commun. 2018 9 2359 10.1038/s41467-018-04791-8 29907766
340. Li D. Huang S. Zhu J. Hu T. Han Z. Zhang S. Zhao J. Chen F. Lei P. Exosomes from mir-21-5p-increased neurons play a role in neuroprotection by suppressing rab11a-mediated neuronal autophagy in vitro after traumatic brain injury Med. Sci. Monit. 2019 25 1871 1885 10.12659/MSM.915727 30860987
341. Pomatto M.A.C. Bussolati B. D’Antico S. Ghiotto S. Tetta C. Brizzi M.F. Camussi G. Improved loading of plasma-derived extracellular vesicles to encapsulate antitumor mirnas Mol. Ther. Methods Clin. Dev. 2019 13 133 144 10.1016/j.omtm.2019.01.001 30788382
342. Xie C. Du L.Y. Guo F. Li X. Cheng B. Exosomes derived from microrna-101-3p-overexpressing human bone marrow mesenchymal stem cells suppress oral cancer cell proliferation, invasion, and migration Mol. Cell Biochem. 2019 458 11 26 10.1007/s11010-019-03526-7 31165315
343. Yang J. Zhang X. Chen X. Wang L. Yang G. Exosome mediated delivery of mir-124 promotes neurogenesis after ischemia Mol. Ther. Nucleic. Acids. 2017 7 278 287 10.1016/j.omtn.2017.04.010 28624203
344. Baldari S. Di Rocco G. Magenta A. Picozza M. Toietta G. Extracellular vesicles-encapsulated microrna-125b produced in genetically modified mesenchymal stromal cells inhibits hepatocellular carcinoma cell proliferation Cells 2019 8 1560 10.3390/cells8121560
345. Liu T. Zhang X. Du L. Wang Y. Liu X. Tian H. Wang L. Li P. Zhao Y. Duan W. Exosome-transmitted mir-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer Mol. Cancer 2019 18 43 10.1186/s12943-019-0981-7 30890168
346. Zou X. Yuan M. Zhang T. Wei H. Xu S. Jiang N. Zheng N. Wu Z. Extracellular vesicles expressing a single-chain variable fragment of an hiv-1 specific antibody selectively target env(+) tissues Theranostics 2019 9 5657 5671 10.7150/thno.33925 31534509
347. Ding Y. Cao F. Sun H. Wang Y. Liu S. Wu Y. Cui Q. Mei W. Li F. Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous mir-145-5p to inhibit pancreatic ductal adenocarcinoma progression Cancer Lett. 2019 442 351 361 10.1016/j.canlet.2018.10.039 30419348
348. Wu H. Fan H. Shou Z. Xu M. Chen Q. Ai C. Dong Y. Liu Y. Nan Z. Wang Y. Extracellular vesicles containing mir-146a attenuate experimental colitis by targeting traf6 and irak1 Int. Immunopharmacol. 2019 68 204 212 10.1016/j.intimp.2018.12.043 30654310
349. Fang S.B. Zhang H.Y. Wang C. He B.X. Liu X.Q. Meng X.C. Peng Y.Q. Xu Z.B. Fan X.L. Wu Z.J. Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of mir-146a-5p J. Extracell Vesicles 2020 9 1723260 10.1080/20013078.2020.1723260 32128074
350. Yuan L. Liu Y. Qu Y. Liu L. Li H. Exosomes derived from microrna-148b-3p-overexpressing human umbilical cord mesenchymal stem cells restrain breast cancer progression Front. Oncol. 2019 9 1076 10.3389/fonc.2019.01076 31696054
351. Yu L. Gui S. Liu Y. Qiu X. Zhang G. Zhang X.a. Pan J. Fan J. Qi S. Qiu B. Exosomes derived from microrna-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating agap2 Aging (Albany NY) 2019 11 5300 5318 10.18632/aging.102092 31386624
352. Ma X. Wang J. Li J. Ma C. Chen S. Lei W. Yang Y. Liu S. Bihl J. Chen C. Loading mir-210 in endothelial progenitor cells derived exosomes boosts their beneficial effects on hypoxia/reoxygeneation-injured human endothelial cells via protecting mitochondrial function Cell Physiol. Biochem. 2018 46 664 675 10.1159/000488635 29621777
353. Wang N. Chen C. Yang D. Liao Q. Luo H. Wang X. Zhou F. Yang X. Yang J. Zeng C. Mesenchymal stem cells-derived extracellular vesicles, via mir-210, improve infarcted cardiac function by promotion of angiogenesis Biochim. Biophys. Acta Mol. Basis Dis. 2017 1863 2085 2092 10.1016/j.bbadis.2017.02.023 28249798
354. Rong Y. Zhang J. Jiang D. Ji C. Liu W. Wang J. Ge X. Tang P. Yu S. Cui W. Hypoxic pretreatment of small extracellular vesicles mediates cartilage repair in osteoarthritis by delivering mir-216a-5p Acta Biomater 2021 122 325 342 10.1016/j.actbio.2020.12.034 33348062
355. Li X. Liu L.L. Yao J.L. Wang K. Ai H. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles inhibit endometrial cancer cell proliferation and migration through delivery of exogenous mir-302a Stem Cells Int. 2019 2019 8108576 10.1155/2019/8108576 31001342
356. Zhou Y. Yamamoto Y. Takeshita F. Yamamoto T. Xiao Z. Ochiya T. Delivery of mir-424-5p via extracellular vesicles promotes the apoptosis of mda-mb-231 tnbc cells in the tumor microenvironment Int. J. Mol. Sci 2021 22 844 10.3390/ijms22020844
357. Jeong K. Yu Y.J. You J.Y. Rhee W.J. Kim J.A. Exosome-mediated microrna-497 delivery for anti-cancer therapy in a microfluidic 3d lung cancer model Lab. A Chip 2020 20 548 557 10.1039/C9LC00958B
358. Han M. Hu J. Lu P. Cao H. Yu C. Li X. Qian X. Yang X. Yang Y. Han N. Exosome-transmitted mir-567 reverses trastuzumab resistance by inhibiting atg5 in breast cancer Cell Death Dis. 2020 11 43 10.1038/s41419-020-2250-5 31969559
359. Rodrigues-Junior D.M. Pelarin M.F.A. Nader H.B. Vettore A.L. Pinhal M.A.S. Microrna-1252-5p associated with extracellular vesicles enhances bortezomib sensitivity in multiple myeloma cells by targeting heparanase Onco Targets Ther. 2021 14 455 467 10.2147/OTT.S286751 33488100
360. Song Y. Zhang C. Zhang J. Jiao Z. Dong N. Wang G. Wang Z. Wang L. Localized injection of mirna-21-enriched extracellular vesicles effectively restores cardiac function after myocardial infarction Theranostics 2019 9 2346 2360 10.7150/thno.29945 31149048
361. Nie H. Xie X. Zhang D. Zhou Y. Li B. Li F. Li F. Cheng Y. Mei H. Meng H. Use of lung-specific exosomes for mirna-126 delivery in non-small cell lung cancer Nanoscale 2020 12 877 887 10.1039/C9NR09011H 31833519
362. Bhaskaran V. Nowicki M.O. Idriss M. Jimenez M.A. Lugli G. Hayes J.L. Mahmoud A.B. Zane R.E. Passaro C. Ligon K.L. The functional synergism of microrna clustering provides therapeutically relevant epigenetic interference in glioblastoma Nat. Commun. 2019 10 442 10.1038/s41467-019-08390-z 30683859
363. Kim R. Lee S. Lee J. Kim M. Kim W.J. Lee H.W. Lee M.Y. Kim J. Chang W. Exosomes derived from microrna-584 transfected mesenchymal stem cells: Novel alternative therapeutic vehicles for cancer therapy BMB Rep. 2018 51 406 411 10.5483/BMBRep.2018.51.8.105 29966581
364. Tsai S.-J. Guo C. Atai N.A. Gould S.J. Exosome-mediated mrna delivery for SARS-CoV-2 vaccination bioRxiv 2020 297 2020-11 10.1101/2020.11.06.371419
365. Kojima R. Bojar D. Rizzi G. Hamri G.C.-E. El-Baba M.D. Saxena P. Ausländer S. Tan K.R. Fussenegger M. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for parkinson’s disease treatment Nat. Commun. 2018 9 1305 10.1038/s41467-018-03733-8 29610454
366. Erkan E.P. Senfter D. Madlener S. Jungwirth G. Ströbel T. Saydam N. Saydam O. Extracellular vesicle-mediated suicide mrna/protein delivery inhibits glioblastoma tumor growth in vivo Cancer Gene Ther. 2017 24 38 44 10.1038/cgt.2016.78 27982017
367. Forterre A.V. Wang J.H. Delcayre A. Kim K. Green C. Pegram M.D. Jeffrey S.S. Matin A.C. Extracellular vesicle-mediated in vitro transcribed mrna delivery for treatment of her2(+) breast cancer xenografts in mice by prodrug cb1954 without general toxicity Mol. Cancer Ther. 2020 19 858 867 10.1158/1535-7163.MCT-19-0928 31941722
368. Yang Z. Shi J. Xie J. Wang Y. Sun J. Liu T. Zhao Y. Zhao X. Wang X. Ma Y. Large-scale generation of functional mrna-encapsulating exosomes via cellular nanoporation Nat. Biomed. Eng. 2020 4 69 83 10.1038/s41551-019-0485-1 31844155
369. Tabak S. Feinshtein V. Schreiber-Avissar S. Beit-Yannai E. Non-pigmented ciliary epithelium-derived extracellular vesicles loaded with smad7 sirna attenuate wnt signaling in trabecular meshwork cells in vitro Pharmaceuticals 2021 14 858 10.3390/ph14090858 34577558
370. Zhao L. Gu C. Gan Y. Shao L. Chen H. Zhu H. Exosome-mediated sirna delivery to suppress postoperative breast cancer metastasis J. Control. Release 2020 318 1 15 10.1016/j.jconrel.2019.12.005 31830541
371. Zhang Q. Zhang H. Ning T. Liu D. Deng T. Liu R. Bai M. Zhu K. Li J. Fan Q. Exosome-delivered c-met sirna could reverse chemoresistance to cisplatin in gastric cancer Int. J. Nanomed. 2020 15 2323 2335 10.2147/IJN.S231214
372. Zhang H. Wang Y. Bai M. Wang J. Zhu K. Liu R. Ge S. Li J. Ning T. Deng T. Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor sirna Cancer Sci. 2018 109 629 641 10.1111/cas.13488 29285843
373. Didiot M.C. Hall L.M. Coles A.H. Haraszti R.A. Godinho B.M. Chase K. Sapp E. Ly S. Alterman J.F. Hassler M.R. Exosome-mediated delivery of hydrophobically modified sirna for huntingtin mrna silencing Mol. Ther. 2016 24 1836 1847 10.1038/mt.2016.126 27506293
374. Shokrollahi E. Nourazarian A. Rahbarghazi R. Salimi L. Karbasforush S. Khaksar M. Salarinasab S. Abhari A. Heidarzadeh M. Treatment of human neuroblastoma cell line sh-sy5y with hsp27 sirna tagged-exosomes decreased differentiation rate into mature neurons J. Cell Physiol. 2019 234 21005 21013 10.1002/jcp.28704 31012118
375. Ju Z. Ma J. Wang C. Yu J. Qiao Y. Hei F. Exosomes from ipscs delivering sirna attenuate intracellular adhesion molecule-1 expression and neutrophils adhesion in pulmonary microvascular endothelial cells Inflammation 2017 40 486 496 10.1007/s10753-016-0494-0 28000095
376. Zhou Y. Yuan Y. Liu M. Hu X. Quan Y. Chen X. Tumor-specific delivery of kras sirna with irgd-exosomes efficiently inhibits tumor growth ExRNA 2019 1 28 10.1186/s41544-019-0034-9
377. Liao K. Niu F. Dagur R.S. He M. Tian C. Hu G. Int.ranasal delivery of lincrna-cox2 sirna loaded extracellular vesicles decreases lipopolysaccharide-induced microglial proliferation in mice J. Neuroimmune Pharm. 2020 15 390 399 10.1007/s11481-019-09864-z
378. Guo S. Perets N. Betzer O. Ben-Shaul S. Sheinin A. Michaelevski I. Popovtzer R. Offen D. Levenberg S. Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and tensin homolog sirna repairs complete spinal cord injury ACS Nano 2019 13 10015 10028 10.1021/acsnano.9b01892 31454225
379. Tang T.T. Wang B. Li Z.L. Wen Y. Feng S.T. Wu M. Liu D. Cao J.Y. Yin Q. Yin D. Kim-1 targeted extracellular vesicles: A new therapeutic platform for rnai to treat aki J. Am. Soc. Nephrol. 2021 32 2467 2483 10.1681/ASN.2020111561 34127536
380. Kim H. Mun D. Kang J.Y. Lee S.H. Yun N. Joung B. Improved cardiac-specific delivery of rage sirna within small extracellular vesicles engineered to express intense cardiac targeting peptide attenuates myocarditis Mol. Ther. Nucleic Acids 2021 24 1024 1032 10.1016/j.omtn.2021.04.018 34141457
381. Li H. Yang C. Shi Y. Zhao L. Exosomes derived from sirna against grp78 modified bone-marrow-derived mesenchymal stem cells suppress sorafenib resistance in hepatocellular carcinoma J. Nanobiotechnol. 2018 16 103 10.1186/s12951-018-0429-z
382. Aqil F. Munagala R. Jeyabalan J. Agrawal A.K. Kyakulaga A.-H. Wilcher S.A. Gupta R.C. Milk exosomes—Natural nanoparticles for sirna delivery Cancer Lett. 2019 449 186 195 10.1016/j.canlet.2019.02.011 30771430
383. Reshke R. Taylor J.A. Savard A. Guo H. Rhym L.H. Kowalski P.S. Trung M.T. Campbell C. Little W. Anderson D.G. Reduction of the therapeutic dose of silencing rna by packaging it in extracellular vesicles via a pre-microrna backbone Nat. Biomed. Eng. 2020 4 52 68 10.1038/s41551-019-0502-4 31937944
384. Dong L. Ding C. Zheng T. Pu Y. Liu J. Zhang W. Xue F. Kang P. Ma Y. Wang X. Extracellular vesicles from human umbilical cord mesenchymal stem cells treated with sirna against elfn1-as1 suppress colon adenocarcinoma proliferation and migration Am. J. Transl Res. 2019 11 6989 6999 31814902
385. Kamerkar S. LeBleu V.S. Sugimoto H. Yang S. Ruivo C.F. Melo S.A. Lee J.J. Kalluri R. Exosomes facilitate therapeutic targeting of oncogenic kras in pancreatic cancer Nature 2017 546 498 503 10.1038/nature22341 28607485
386. Wang C. Chen L. Huang Y. Li K. Jinye A. Fan T. Zhao R. Xia X. Shen B. Du J. Exosome-delivered trpp2 sirna inhibits the epithelial-mesenchymal transition of fadu cells Oncol. Lett. 2019 17 1953 1961 10.3892/ol.2018.9752 30675260
387. Yang T. Fogarty B. LaForge B. Aziz S. Pham T. Lai L. Bai S. Delivery of small interfering rna to inhibit vascular endothelial growth factor in zebrafish using natural brain endothelia cell-secreted exosome nanovesicles for the treatment of brain cancer AAPS. J. 2017 19 475 486 10.1208/s12248-016-0015-y 27882487
388. Anticoli S. Manfredi F. Chiozzini C. Arenaccio C. Olivetta E. Ferrantelli F. Capocefalo A. Falcone E. Ruggieri A. Federico M. An exosome-based vaccine platform imparts cytotoxic t lymphocyte immunity against viral antigens Biotechnol. J. 2018 13 e1700443 10.1002/biot.201700443 29274250
389. Daraee H. Etemadi A. Kouhi M. Alimirzalu S. Akbarzadeh A. Application of liposomes in medicine and drug delivery Artif. Cells Nanomed. Biotechnol. 2016 44 381 391 10.3109/21691401.2014.953633 25222036
390. Sabanovic B. Piva F. Cecati M. Giulietti M. Promising extracellular vesicle-based vaccines against viruses, including SARS-CoV-2 Biology 2021 10 94 10.3390/biology10020094 33513850
391. Zhang C. Maruggi G. Shan H. Li J. Advances in mrna vaccines for infectious diseases Front. Immunol. 2019 10 594 10.3389/fimmu.2019.00594 30972078
392. Baden L.R. El Sahly H.M. Essink B. Kotloff K. Frey S. Novak R. Diemert D. Spector S.A. Rouphael N. Creech C.B. Efficacy and safety of the mrna-1273 SARS-CoV-2 vaccine N. Engl. J. Med. 2020 384 403 416 10.1056/NEJMoa2035389 33378609

